YUH-JYH JONG
CHAIR Professor YUH-JYH JONG
|
Education
|
|
Doctor of Medicine: Kaohsiung Medical College, Taiwan
Master of Medicine: Kaohsiung Medical College, Taiwan
D. M. Sci.: Tokyo Women’s Medical University, Japan
|
|
Current Position
|
|
Chair Professor, Kaohsiung Medical University (KMU)
Chair Professor, National Yang Ming Chiao Tung University
Visiting Staff, Departments of Pediatrics and Laboratory Medicine, KMU Hospital
Honorary Director, Taiwan Child Neurology Society
Director, Taiwan Human Genetics Society
Executive Director, Formosan Medical Association
Executive Director, Taiwan SMA Families
|
|
Experience
|
|
(1) President, KMU (2018/8-2021/8)
(2) Professor & Dean, College of Biological Science and Technology, National Chiao Tung University (NCTU) (2013/8-2018/8)
(3) Senior University Counselor, NCTU (2012/8-2013/7)
(4) Vice President, KMU (2006/7-2012/6)
(5) Professor, Graduate Institute of Clinical Medicine, College of Medicine, KMU (2015/8-present)
(6) Professor, Graduate Institute of Medicine, College of Medicine, KMU (2005/8-2015/7)
(7) Chair, Graduate Institute of Medicine, College of Medicine, KMU (2004/8-2006/7)
(8) Vice Superintendent, KMU Hospital; Chair, Departments of Pediatrics/Clinical Research, KMU Hospital; Director, Departments of Pediatrics and Medical Genetics, College of Medicine, KMU (2003/8-2006/7)
(9) Superintendent, KMU Hsiao-Kang Hospital; Director, Department of Laboratory Medicine, KMU Hsiao-Kang Hospital (2003/8-2006/7)
(10) Professor, Departments of Pediatrics/ Laboratory Medicine, College of Medicine, KMU (2000/8-2005/7)
|
|
Awards
|
|
1998 Kaohsiung Medical College Education Reform Contribution Award
2004 Led Hsiao-Kang Hospital to be recognized by the Department of Health of the Executive Yuan as a Medical Institution with Meritorious Service in the Prevention and Treatment of SARS
2005 The 3rd National Golden Palm Tree Award
2011 Taiwan Pediatric Education Contribution Award
2013 Taiwan Pediatric Association Award
2020 Taiwan Child Neurology Society Contribution Award
2021 Taiwan Medical Association Taiwan Medical Model Award
|
|
Specialty and Research Field
|
|
Pediatrics, Pediatric NeurologyNeuromuscular Diseases, Translational Medicine, Precision Medicine
|
|
Representative Publications
|
|
1. Chen TH, Chang SH, Wu YF, Yen YP, Hsu FY, Chen YC, Ming Y, Hsu HC, Su YC, Wong ST, Hung JH, Chiou SH, Jong YJ*, Chen JA*. MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice. Mol Ther Nucleic Acids 2023;32:144-60.
2. Crawford TO*, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, Kuntz NL, Nazario AN, Parsons JA, Pechmann A, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Zhu C, Raynaud S, Lago TR, Paradis AD, Foster R, Chin R, Berger Z; NURTURE Study Group. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 2023 ;68(2):157-70.
3. Chou SH, Lin SY, Wu MH, Tien YC, Jong YJ, Liang WC, Lu YM, Shih CL, Lu CC*. Intravenous tranexamic acid reduces blood loss and transfusion volume in scoliosis surgery for spinal muscular atrophy: results of a 20-year retrospective analysis. Int J Environ Res Public Health 2021;18(19):9959.
4. Sophelia Chan HS, Chae JH, Chien YH, Ko TS, Lee JH, Lee YJ, Nam SO, Jong YJ* Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions. J Neurol Neurosurg Psychiatry 2021;92(11):1244-6.
5. Ou SF, Ho CS, Lee WT, Lin KL, Cynthia C Jones, Jong YJ*, SMA Study Group. Natural history in spinal muscular atrophy type I in Taiwanese population: A longitudinal study. Brain Dev 2021;43(1):127-34.
6. Liang WC, Jong YJ*, Wang CH, Wang CH, Tian X, Chen WZ, Kan TM, Narihiro Minami, Ichizo Nishino, C Wong LJ. Clinical, pathological, imaging, and genetic characterization in a Taiwanese cohort with limb-girdle muscular dystrophy. Orphanet J Rare Dis 2020;15(1):160.
7. Shen PC, Lu CC, Liang WC, Tien YC, Jong YJ, Lu YM, Liu ZM, Shih CL, Chou SH*. Predictors for Deformity Progression in a Spinal Muscular Atrophy Cohort After Scoliosis Correction Surgery. Clin Spine Surg. 2020;33(8):E407-14.
8. De Vivo DC*, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Staropoli JF, Kerr D, Sandrock AW, Stebbins C, Petrillo M, Braley G, Johnson K, Foster R, Gheuens S, Bhan I, Reyna SP, Fradette S, Farwell W, NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019;29(11):842-56.
9. Chen TH, Liang WC, Chen IC, Liu YC, Hsu JH, Jong YJ*. Combined noninvasive ventilation and mechanical insufflator–exsufflator for acute respiratory failure in patients with neuromuscular disease: effectiveness and outcome predictors. Ther Adv Respir Dis 2019;13:1753466619875928.
10. Wang CC, Chen CA*, Jong YJ, Kou HS. Specific gene capture combined with restriction-fragment release for directly fluorescent genotyping of single-nucleotide polymorphisms in diagnosing spinal muscular atrophy. Anal Chem 2018;90(19):11599-606.
11. Finkel RS*, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377(18):1723-32.
12. Victor RG*, Sweeney HL, Finkel R, McDonald CM, Byrne B, Eagle M, Goemans N, Vandenborne K, Dubrovsky AL, Topaloglu H, Miceli MC, Furlong P, Landry J, Elashoff R, Cox D, Tadalafil DMD Study Group. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology 2017;89(17):1811-20.
13. Chien YH, Chiang SC, Weng WC, Lee NC, Lin CJ, Hsieh WS, Lee WT, Jong YJ, Ko TM, Hwu WL*. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr 2017;190:124-9.
14. Lin TL, Chen TH, Hsu YY, Cheng YH, Juang BT, Jong YJ*. Selective neuromuscular denervation in Taiwanese severe spinal muscular atrophy mouse can be reversed by morpholino antisense oligonucleotides. PLoS One 2016;11(4):e0154723.
15. Tian X, Liang WC, Feng Y, Wang J, Zhang VW, Chou CH, Huang HD, Lam CW, Hsu YY, Lin TS, Chen WT, Wong LJ*, Jong YJ*. Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS. Neurol Genet 2015;1(2):e14.
16. Chen TH, Hsu JH, Wu JR, Dai ZK, Chen IC, Liang WC, Yang SN, Jong YJ*. Combined noninvasive ventilation and mechanical in-exsufflator in the treatment of pediatric acute neuromuscular respiratory failure. Pediatric Pulmonol 2014;49(6):589-96.
17. Liang WC, Hayashi YK, Ogawa M, Wang CH, Huang WT, Nishino I, Jong YJ*. Limb-girdle muscular dystrophy type 2I is not rare in Taiwan. Neuromuscu Disord 2013;23(8):675-81.
18. Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK, Nishino I, Lin CW, Shih HH, Huang CC, Liang WC, Wang WF, Jong YJ*. Infantile facioscapulohumeral muscular dystrophy revisted: Expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord 2013;23(4):298-305.
19. Hsu YY, Jong YJ, Tsai HH, Tseng YT, An LM, Lo YC*. Triptolide increases SMN transcript and protein levels in human SMA fibroblasts and improves survival in SMA-like mice. Br J Pharmacol 2012;166(3):1114-26.
20. Chen YS, Shih HH, Chen TH, Kuo CH, Jong YJ*. Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III. J Pediatr 2012;160(3):447-51.
21. Chen TH, Chang JG, Yang YH, Mai HH, Liang WC, Wu YG, Wang HY, Huang YB, Wu SM, Chen YC, Yang SN, Jong YJ*. A randomized, double-blind, placebo-controlled trial of hydroxyrea in spinal muscular atrophy. Neurology 2010;75(24):2190-7.
22. Liang WC, Ohkuma A, Hayashi YK, López LC, Hirano M, Nonaka I, Noguchi S, Chen LH, Jong YJ*, Nishino I*. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl CoA dehydrogenase deficiency. Neuromusc Disord 2009;19(3):212-6.
23. Liang WC, Yuo CY, Liu CY, Lee CS, Goto K, Hayashi YK, Jong YJ*. Novel LMNA mutation in a Taiwanese family with autosomal dominant Emery-Dreifuss muscular dystrophy. J Formos Med Assoc 2007;106(2 Suppl):S27-31.
24. Chang HC, Hung WC, Chuang YJ, Jong YJ*. Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem Int 2004;45(7):1107-12.
25. Chang JG*, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001;98(17):9808-13.
26. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H*. A mouse model for spinal muscular atrophy. Nature Genet 2000;24(1):66-70.
27. Jong YJ*, Chang JG, Lin SP, Yang TY, Wang JC, Chang CP, Lee CC, Li H, Hsieh-Li HM, Tsai CH. Analysis of the mRNA transcripts of the survival motor neuron (SMN) gene in the tissue of an SMA fetus and the peripheral blood mononuclear cells of normals, carriers and SMA patients. J Neurol Sci 2000;173(2):147-53.
28. Jong YJ*, Chang JG, Wu JR. Large-scale deletions in a Chinese infant associated with a variant form of Werdnig-Hoffmann disease. Neurology 1998;51(3):878-9.
29. Chang JG*, Jong YJ, Huang JM, Wang WS, Yang TY, Chang CP, Chen YJ, and Lin SP: Molecular basis of spinal muscular atrophy in Chinese. Am J Hum Genet 1995;57(6):1503-05.
30. Liu GC*, Jong YJ, Chiang CH, Jaw TS. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology 1993;186(2):475-80.
31. Liu GC*, Jong YJ, Chiang CH, Yang CW. Spinal muscular atrophy: MR evaluation. Pediatr Radiol 1992;22(8):584-6.
32. Jong YJ*. Chuang YH, Chen SS, Chen BH, Chiang CH. Dystrophin immunostaining of muscle from Chinese patients with various neuromuscular diseases. J Formos Med Assoc 1991;90(12):1143-8.
|
MEI-REN PAN
MEI-REN PAN
|
Education
|
|
PhD, Graduate Institute of Medicine, Kaohsiung Medical University, Taiwan
|
|
◎專長領域◎
|
|
Cancer cell metastasis; lymphatic angiogenesis; cancer cell drug resistance mechanism; gene mutation repair mechanism
|
|
Intramural Experience
|
|
MD Anderson Cancer Ctr., Houston, TX 博士後研究員 (2008-2011)
國家衛生研究院癌症研究所博士後研究員 (2011-2013)
高雄醫學大學臨床醫學研究所助理教授（2013~2018.01）
高雄醫學大學臨床醫學研究所副教授（2018.02~2021.01）
高雄醫學大學臨床醫學研究所教授（2021.02~）
高雄醫學大學附設中和紀念醫院臨床醫學研究部癌症研究室主任（2021.08~)
|
|
Research Publish
|
|
(Selected)
1. Ou-Yang F, Li CL, Chen CC, Shen YC, Moi SH, Luo CW, Xia W, Wang YN, Lee HH, Wang LH, Wang SC*, Pan MR*, Hou MF*, Hung MC*. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. American Journal of Cancer Research. 2022;12(1):123-137.
2. Kao CN, Moi SH, Hou MF, Luo CW, Chen FM, Pan MR.RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. Journal of personalized medicine. 2021 Jul 13;11(7):655.
3. Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, Wang SC, Pan MR, Yang CH, Wang YL, Yamaguchi H, Pang D, Hortobagyi GN, Yu D, Hung MC. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature communications. 2021 May 13;12(1):2788.
4. Wang HC, Chan LP, Wu CC, Chang SJ, Moi SH, Luo CW, Pan MR. Silencing DNA Polymerase β Induces Aneuploidy as a Biomarker of Poor Prognosis in Oral Squamous Cell Cancer. International Journal of Molecular Sciences. 2021 Feb 27;22(5):2402. doi: 10.3390/ijms22052402.
5. Wang HC, Chou MC, Wu CC, Chan LP, Moi SH, Pan MR*, Liu TC*, Yang CH*. Application of the Interaction between Tissue Immunohistochemistry Staining and Clinicopathological Factors for Evaluating the Risk of Oral Cancer Progression by Hierarchical Clustering Analysis: A Case-Control Study in a Taiwanese Population.Diagnostics (Basel). 2021 May 21;11(6):925.
6. Huang WL, Luo CW, Chou CL, Yang CC, Chen TJ, Li CF, Pan MR. High Expression of UBE2B as a Poor Prognosis Factor in Patients With Rectal Cancer Following Chemoradiotherapy. Anticancer Research. 2020 Nov;40(11):6305-6317. doi: 10.21873/anticanres.
7. Luo CW, Hou MF, Huang CW, Wu CC, Ou-Yang F, Li QL, Wu CC and Pan MR. The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer. American Journal of Cancer Research. 2020 Dec 1;10(12):4325-4341.
8. Hsu YC, Luo CW, Huang WL, Wu CC, Chou CL, Chen CI, Chang SJ, Chai CY, Wang HC, Chen TY, Li CF, Pan MR. BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Radiother Oncol. 2020 Aug;149:249-258. doi: 10.1016/j.radonc.2020.06.023.
9. Pan MR, Wu CC, Kan JY, Li QL, Chang SJ, Wu CC, Li CL, Ou-Yang F, Hou MF, Yip HK, Luo CW. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers (Basel). 2019 Dec 30;12(1):94. doi: 10.3390/cancers12010094.
10. Tsai HL, Pang SY, Wang HC, Luo CW, Li QL, Chen TY, Fang SY, Wang JY, Pan MR. Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer. American Journal ofCancer Research. 2019 Nov; 1;9(11): 2544-2553.
11. Wang HC, Chou CL, Yang CC, Huang WL, Hsu YC, Luo CW, Chen TJ, Li CF, Pan MR. Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy. International Journal of Molecular Sciences. 2019 Aug 21;20(17).pii: E4087. doi: 10.3390/ijms20174087.
12. Hung YH, Hsu MC, Chen LT, Hung WC, Pan MR. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Journal of Clinical Medicine. 2019 Jun 24;8(6). pii:E903. doi: 10.3390/jcm8060903. Review.
13. Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, Yip HK, Luo CW*. FAK is required for tumor metastasis-related fluid microenvironment in triple-negative breast cancer. JournalofClinicalMedicine. 2019Jan2;8(1). pii:E38.doi: 10.3390/jcm8010038.
14.
Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. International Journal of Molecular Sciences. 2018 Nov 13;19(11). pii: E3584. doi: 10.3390/ijms19113584. Review.1.
15. Tian YF, Wang HC, Luo CW, Hung WC, Lin YH, Chen TY, Li CF, Lin CY, Pan MR. Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. American Journal of Cancer Research. 2018 Sep 1;8(9):1812-1822.
16. Luo CW, Hsiao IL, Wang JY, Wu CC, Hung WC, Lin YH, Chen TY, Hsu YC, Cheng TL, Pan MR. Cell Motility Facilitated by Mono(2-ethylhexyl) Phthalate via Activation of the AKT-β-Catenin-IL-8 Axis in Colorectal Cancer. Journal of Agricultural and Food Chemistry. 2018Sep 19;66 (37) :9635-9644.
17. Luo CW, Wu CC, Chang SJ, Chang TM, Chen TY, Chai CY, Chang CL, Hou MF, Pan MR. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.Experimental CellResearch. 2018 Feb 1;363(1):65-72.
18. Pan MR, Hsu MC, Chen LT, Hung WC. Orchestration of H3K27 methylation: mechanisms and therapeutic implication. CellularandMolecularLifeSciences. 2018Jan;75(2):209-223.
19. Hou MF, Luo CW, Chang TM, Hung WC, Chen TY, Tsai YL, Chai CY, Pan MR. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer. ExperimentalCell Research. 2017 Oct 15;359(2):458-465.
20. Luo CW, Wang JY, Hung WC, Peng Guang, Tsai YL, Chang TM, Chai CY, Lin CH and Pan MR. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiotherapy and Oncology. 2017 Sep;124(3):395-402.
21. Yin HL,Wu CC, Lin CH, Chai CY, Hou MF, Chang SJ, Tsai HP, Hung WC, Pan MR* and Luo CW*. Beta1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer. InternationalJournal ofMolecular Sciences2016 Aug31;17(9). pii:E1432.
22. Pan MR, Hsu MC, Chen LT, Shen YS, Hung WC. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget 2016 Sep 20;7(38):61136-61151.
23. Pan MR, Li Kaiyi, Lin SY and Hung WC. Connecting the Dots: From DNA Damage and Repair to Aging. International Journal of Molecular Sciences. 2016 May 6;17(5).
24. Pan MR, Hsu MC, Liu JY, Chen LT, Hung WC. G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation. Scientific Reports. 2015 Dec 21;5:18709.
25. Leu MH*, Huang CC*, Pan MR*, Chen HH, Hung WC. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clinical Cancer Research. 2012; 18(23): 6416-25.
26. Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Research. 2012; 72(11): 2802-13.
27. Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor Treatment. The Journal of Biological Chemistry. 2012; 287 (9): 6764-72.
28. Pan MR, Peng G, Hung WC, Lin SY. Monoubiquitination of H2AX regulates DNA damage response signaling. The Journal of Biological Chemistry. 2011; 286(32): 28599-607.
|
Shu-Pin Huang
|
Personal Data:
Name: Shu-Pin Huang M.D.& Ph.D.
Address: Department of Urology,
Kaohsiung Medical University
No. 100, Shih-Chuan 1st Road , Kaohsiung, TAIWAN 807
Marital Status: Married
Birth Year: 1972
Place of Birth: Kaohsiung, Taiwan
|
|
Current Position: Professor and Visiting Staff
Department of Urology, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, TAIWAN 807
Phone: 886-7-3121101 ext. 6694
Fax: 886-7-3211033
E-mail: shpihu73@gmail.com; shpihu@yahoo.com.tw
Education:
1. School of Medicine, Kaohsiung Medical University (KMU), 1990-1997 (M.D. Degree)
2. Graduate Institute of Medicine, Kaohsiung Medical University (KMU) 1999~2004 (Ph.D. Degree)
Post-Graduate Training:
1. Resident , Dept. of Urology, KMU 1997-1999
2. Chief Resident, Dept. of Urology, KMU, 2000
3. Visiting Staff, Dept. of Urology, KMU, 2000 ~ present
Postdoctoral Research
George Whipple Lab for Cancer Research, University of Rochester Medical Center, NY, USA, 2005~2006
Professional Society Membership:
1. Member of Taiwan Urological Association (TUA)
2. Member of American Urological Association (AUA)
3. Member of European Association of Urology (EAU)
4. Member of Urological Association of Asia (UAA)
Role of PI in Clinical Trials:
|
Protocol Name and Number: Role: PI
|
Study Period
|
|
Protocol number.: 212082PCR3001
An Open-Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy.
|
2012.09.01~2014.12.31
|
|
Protocol Number: MDV3100-14
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
|
2013.11.01~2018.11.01
|
|
Protocol Number: ARI 114265
A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin(0.2mg) with tamsulosin(0.2mg) monotherapy, administered once daily for 2years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia.
|
2014.01.01~2017.12.31
|
|
Protocol Number: 9785-CL-0232
Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
|
2014.05.01~2017.03.31
|
|
Protocol Number: 9785-CL-0403
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (UPWARD)
|
2014-7-30~2018-06-30
|
|
Protocol Number: ONC-MA-1001
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis
|
2015~
|
|
Protocol Number: Orion Pharma Protocol: 3104007
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High- Risk Non-Metastatic Castration-Resistant Prostate Cancer
|
2015~
|
|
Protocol Number: MDV3100-13
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
|
2016~
|
|
Bayer ARASENS 17777 study
A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer
|
2017~
|
|
Protocol Number: MVT-601-3201
HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
|
2017~
|
|
Protocol Number: 9785-CL-0335
ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
|
2017~
|
|
Protocol Number: CO39303
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TESTING IPATASERIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
|
2017~ 2018
|
Biography;
Prof/Dr. Shu-Pin Huang has received his PhD in Graduate of Medicine, Kaohsiung Medical University during the period of 1999 to 2004. Currently, he is working as Professor and Visiting Staff in Department of Urology, Kaohsiung Medical University Hospital & Kaohsiung Medical University in Taiwan. He is serving as a reviewer of several reputed journals like New England Journal of Medicine, Clinical Cancer Research, PLOS One, Cancer, Clinica Chimic Acta, Annals of Surgical Oncology, Journal of Endourology, International Journal of Oncology, Medicine, J Endourology, … etc. Prof Huang has published over 140 research articles in peer-review SCI journals. He is a member of Urological Association of Taiwan, American Urological Association (AUA) and European Association of Urology (EAU) and also served as Academic Editor for Medicine and Member of Editorial Board of International Journal of Urology. In additional to general Urology, Renal Transplantation and Robotic Surgery in Urology Oncology (majority on radical prostatectomy and Uro-oncology), Dr. Huang’s research interests were mainly focus on: Prostate Cancer, Molecular Epidemiology, Pharmacogenomic studies, Metabolic syndrome, Endocrine-Related Cancer, Urolithiasis, Andrology, Male Erectile dysfunction … etc.
Selected Published Papers:
1. Huang CH, Wang SC, Chen IC, Chen YT, Liu PL, Fang SH, Huang SP, Yeh HC, Liu CC, Lee PY, Lin TC, Cheng WC, Su CC, Wu HE, Chen YR, Li CY. (2021, Jun). Protective Effect of Piplartine against LPS-Induced Sepsis through Attenuating the MAPKs/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. Pharmaceuticals (Basel), Jun 18;14(6):588. .
2. Huang SP, Chen LC, Chen YT, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, Jun). PTBP1 Genetic Variants Affect the Clinical Response to Androgen-deprivation Therapy in Patients With Prostate Cancer. Cancer Genomics Proteomics., 18(3):325-334.. 本人為第一作者.
3. Tsai YC, Huang CY, Hsueh YM, Fan YC, Fong YC, Huang SP, Geng JH, Chen LC, Lu TL, Bao BY. (2021, Jun). Genetic variants in MAPK10 modify renal cell carcinoma susceptibility and clinical outcomes. Life sciences, 275:119396.
4. Huang SP, Chen YT, Chen LC, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, May). NRG1 Genetic Variant Influences the Efficacy of Androgen- Deprivation Therapy in Men with Prostate Cancer. Biomedicines, 9(5):528. 本人為第一作者.
5. Su CC, Wang SC, Chen IC, Chiu FY, Liu PL, Huang CH, Huang KH, Fang SH, Cheng WC, Huang SP, Yeh HC, Liu CC, Lee PY, Huang MY, Li CY. (2021, May). Zerumbone Suppresses the LPS-Induced Inflammatory Response and Represses Activation of the NLRP3 Inflammasome in Macrophages. Front Pharmacol. , 12:652860.
6. Wang SH, Huang SP, Pan YJ, Hsiao PC, Li CY, Chen LC, Yu CC, Huang CY, Lin VC, Lu TL, Bao BY. (2021, May). Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer. Am J Cancer Res, 11(5):2331-2342.
7. Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. (2021, Feb). Role of the NLRP3 Inflammasome: Insights Into Cancer Hallmarks. Frontiers in Immunology, Feb 3;11:610492.. 本人為通訊作者.
8. Liu CC, Huang SP, Hsieh TJ, Lee CH, Cheng KH, Huang TY, Geng JH, Li CC, Wu WJ, Lee YC. (2021, Feb). Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome. Andrology, 9(3):863-872. .
9. Huang CY, Huang SP, Hsueh YM, Chen LC, Lu TL, Bao BY. (2020, Nov). Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma. Cancer Genomics Proteomics., 17(6):827-833..
10. Li CC, Chien TM, Huang SP, Yeh HC, Lee HY, Ke HL, Wen SC, Chang WC, Juan YS, Chou YH, Wu WJ. (2020, Nov). Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors. J Clin Med., 9(11):3658..
11. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators (2020, Sep). Nonmetastatic, Castration- Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med, 383(11):1040-1049..
12. Liu CC, Hsieh TJ, Wu CF, Lee CH, Tsai YC, Huang TY, Wen SC, Lee CH, Chien TM, Lee YC, Huang SP, Li CC, Chou YH, Wu WJ, Wu MT. (2020, Sep). Interrelationship of environmental melamine exposure, biomarkers of oxidative stress and early kidney injury. J Hazard Mater., 396:122726.
13. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. (2020, Jun). Oral Relugolix for Androgen- Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. , 382(23):2187-2196.
14. Ke CC, Chen LC, Yu CC, Cheng WC, Huang CY, Lin VC, Lu TL, Huang SP, Bao BY. (2020, May). Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men. Cancers (Basel)., ; 12(5):1346 . 本人為通訊作者.
15. Yu CC, Chen LC, Huang CY, Lin VC, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Apr). Genetic association analysis identifies a role for ANO5 in prostate cancer progression. Cancer Med., 9(7):2372-2378. 本人為通訊作者.
16. Yu CC, Chen LC, Lin WH, Lin VC, Huang CY, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Mar). Genetic Association Analysis of Cell Cycle Regulators Reveals YWHAZ Has Prognostic Significance in Prostate Cancer. Cancer Genomics Proteomics. , 17(2):209-216. 本人為通訊作者.
17. Lee CH, Chen LC, Yu CC, Lin WH, Lin VC, Huang CY, Lu TL, Huang SP, Bao BY. (2019, Nov). Prognostic Value of CD1B in Localised Prostate Cancer.. International Journal of Environment Research and Public Health, 16(23). pii: E4723. 本人為通訊作者.
18. Yu CC, Chen LC, Lin VC, Huang CY, Cheng WC, Hsieh AR, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Jun). Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.. Cancer Medicine, 8(6): 2777–2783. 本人為通訊作者.
19. Su CC, Hsieh KL, Liu PL, Yeh HC, Huang SP, Fang SH, Cheng WC, Huang KH, Chiu FY, Lin IL, Huang MY, Li CY (2019, Apr). AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.. International Journal of Molecular Sciences, 20(7): 1647.
20. Yu CC, Chen LC, Chiou CY, Chang YJ, Lin VC, Huang CY, Lin IL, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Apr). Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression. Cancer Cell International, 19: 87. 本人為通訊作者.
21. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR1; ARAMIS Investigators. (2019, Mar). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.. The New England Journal of Medicine, 380(13):1235-1246..
22. Huang CY, Hsueh YM, Chen LC, Cheng WC, Yu CC, Chen WJ, Lu TL, Lan KJ, Lee CH, Huang SP, Bao BY (2018, Nov). Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival. Cancer Medicine, 7(12): 6104–6111. 本人為通訊作者.
23. Liu CC, Lee YC, Huang SP, Cheng KH, Hsieh TJ, Huang TY, Lee CH, Geng JH, Li CC, Wu WJ. (2018, Nov). Hepatocyte Nuclear Factor-4α P2 Promoter Variants Are Associated With the Risk of Metabolic Syndrome and Testosterone Deficiency in Aging Taiwanese Men.. Journal of Sexual Medicine, 15(11): 1527- 1536.
24. Chen YC, Chen HW, Lee CH, Huang SP. (2018, Oct). A Rare Delayed Bladder Migration of a Hem-o-lok Clip 5 Years after Robotic-Assisted Radical Prostatectomy.. Urologia Internationalis, 19:1-3. 本人為通訊作者.
25. Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, Li CR, Lin CY, Huang SP, Chen LT, Tsai KK. (2018, Sep). ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling. Oncogene, 38(8):1340-1353.
26. Chen YC, Chen HW, Huang SP, Yeh HC, Li CC. (2018, Aug). Adequate rectal preparation reduces hospital admission for urosepsis after transrectal ultrasound - guided prostate biopsy.. International Braz J Urol , 5;44.
27. Huang EY, Chang YJ, Huang SP, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Bao BY. (2018, Jul). A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer. Journal of Cellular and Molecular medicine, 22(7); 3661-3670. 本人為第一作者.
28. Liu CC, Hsieh TJ, Wu CF, Tsai YC, Huang SP, Lee YC, Huang TY, Shen JT, Chou YH, Huang CN, Wu WJ, Wu MT. (2017, Dec). Urinary melamine excretion and increased markers of renal tubular injury in patients with calcium urolithiasis: A cross-sectional study.. Environmental Pollution, 231(Pt 2):1284- 1290.
29. Cha TL, Wu TT, Vogelzang NJ, Huang CY, Huang SP, Lin CC, Ou YC, Pang ST, Shen DH, Wu WJ, Chang WY. (2017, Nov). Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. Journal of the Formosan Medical Association, 116(11):825-836.
30. Lin VC, Huang SP, Huang CY, Yu CC, Yin HL, Huang TY, Lee CH, Lu TL, Bao BY. (2017, Sep). Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.. International Journal of Medical Sciences, 14(12):1301-1306.
31. Lin YC, Hour TC, Tsai YC, Huang SP, Wu WJ, Chen CH, Pu YS, Chung SD, Huang CY. (2017, Sep). Preliminary evidence of polymorphisms of cell cycle regulatory genes and their roles in urinary tract urothelial cancer susceptibility and prognosis in a Taiwan population.. Urologic Oncology, 35(9):543.e7- 543.e16.
32. Liu CC, Huang SP, Cheng KH, Hsieh TJ, Huang CN, Wang CJ, Yeh HC, Tsai CC, Bao BY, Wu WJ, Lee YC. (2017, Jun). Lower SHBG level is associated with higher leptin and lower adiponectin levels as well as metabolic syndrome, independent of testosterone.. Scientific Reports, 35(9):543.e7-543.e16.
33. Lin VC, Huang SP, Ting HJ, Ma WL, Yu CC, Huang CY, Yin HL, Huang TY, Lee CH, Chang TY, Lu TL, Bao BY. (2017, May). Vitamin D receptor-binding site variants affect prostate cancer progression.. Oncotarget, 8(43):74119-74128.
34. Lee YC, Huang SP, Tsai CC, Cheng KH, Juan YS, Wu WJ, Bao BY, Huang CN, Wang CJ, Liu CC. (2017, Apr). Associations of VEGF Gene Polymorphisms With Erectile Dysfunction and Related Risk Factors.. Journal of Sexual Medicine, 14(4):510-517.
35. Geng JH, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Huang SP, Bao BY. (2016, Nov). Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.. International Journal of Molecular Sciences , 17(12):1970. 本人為通訊作者.
36. Lin VC, Lu TL, Yin HL, Yang SF, Lee YC, Liu CC, Huang CY, Yu CC, Chang TY, Huang SP, Bao BY. (2016, Nov). Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer. International Journal of Molecular Sciences, 17(12):1996. . 本人為通訊作者.
37. Lee YC, Huang SP, Juan YS, Huang TY, Liu CC. (2016, Sep). Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males.. The Aging Male, 19(3):197-201.
38. Chien TM, Lu YM, Geng JH, Huang TY, Ke HL, Huang CN, Li CC, Chou YH, Wu WJ, Huang SP. (2016, Aug). Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients. Asian Pacific Journal of Cancer Prevention, , 17(3):1187-91. 本人為通訊作者.
39. Lee CH, Pao JB, Lu TL, Lee HZ, Lee YC, Liu CC, Huang CY, Lin VC, Yu CC, Yin HL, Huang SP, Bao BY. (2016, Aug). Prognostic Value of Prostaglandin- endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy. International Journal of Medical Sciences, 13(9):696- 700. 本人為通訊作者.
40. Lee YC, Juan YS, Liu CC, Bao BY, Wang CJ, Wu WJ, Huang CN, Huang SP. (2016, Aug). The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms. BJU International, 118(2):313-9.. 本人為通訊作者.
41. Yeh HC, Chien TM, Wu WJ, Li CC, Li WM, Ke HL, Chou YH, Wang CJ, Huang SP, Li CF, Liang PI, Huang CN. (2016, Aug). Is preoperative anemia a risk factor for upper tract urothelial carcinoma following radical nephroureterectomy? Urologic Oncology.34(8):337.e1-9.
42. Tai SY, Huang SP, Bao BY, Wu MT. (2016, Jul). Urinary melatonin- sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.. Scientific Reports, 6:29606.
43. Tai SY, Hsieh HM, Huang SP, Wu MT. (2016, Mar). Hair dye use, regular exercise, and the risk and prognosis of prostate cancer: multicenter case-control and case-only studies. BMC Cancer. 16:242.本人為通訊作者.
44. Bao BY, Lin VC, Yu CC, Yin HL, Chang TY, Lu TL, Lee HZ, Pao JB, Huang CY, Huang SP. (2016, Feb). Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival.. Scientific Reports. 6:22124. 本人為通訊作者.
45. Yang SM, Huang CY, Shiue HS, Huang SP, Pu YS, Chen WJ, Lin YC, Hsueh YM. (2015, Dec). Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma.. PLOS ONE, 10(12):e0145410.
46. Geng JH, Huang SP, Huang CY. (2015, Oct). Prognostic factors in Taiwanese patients with penile-invasive squamous cell carcinoma.. Kaohsiung Journal of Medical Sciences , 31(10):523-8..
47. Yeh HC, Jan HC, Wu WJ, Li CC, Li WM, Ke HL, Huang SP, Liu CC, Lee YC, Yang SF, Liang PI, Huang CN. (2015, Oct). Concurrent Preoperative Presence of Hydronephrosis and Flank Pain Independently Predicts Worse Outcome of Upper Tract Urothelial Carcinoma.. PLOS ONE, 10(10):e0139624.
48. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Lu TL, Chiang HC, Bao BY. (2015, Sep). Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.. Scientific Reports, 5:14045.
49. Liu CC, Hsieh HM, Wu CF, Hsieh TJ, Huang SP, Chou YH, Huang CN, Wu WJ, Wu MT. (2015, Apr). Long-term prescription of α-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention-a nationwide population- based study. PLOS One, 10(4):e0122494.
50. Chen CS, Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Bao BY. (2015, Feb). Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.. Int J Med Sci., 12(3):243-7.
51. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Juang SH, Bao BY. (2015, Feb). Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Scientific Reports. 5:8556.
52. Cheng KH, Hsi E, Liu CC, Huang CN, Lee YC, Chu CS, Bao BY, Chang CF, Huang SP, Kuo PL, Lai WT. (2015, Jan). The Associations of Novel Vitamin D3 Metabolic Gene CYP27A1 Polymorphism, Adiponectin/Leptin Ratio, and Metabolic Syndrome in Middle-Aged Taiwanese Males. International Journal of Endocrinology, 2015:658151.
53. Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY. (2014, Dec). Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer, 135(11):2661-7. NSC 100-2314-B-039-009-MY3. 本人為第一作者.
54. Lee HY, Wu WJ, Huang CH, Chou YH, Huang CN, Lee YC, Yang KF, Lee MH, Huang SP. (2014, Aug). Clinical predictor of survival following docetaxel-based chemotherapy. Oncol Lett. , 8(4):1788-1792. 本人為通訊作者.
55. Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY, Pu YS. (2014, Jun). EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol, 89(4):591-605.
56. Huang TY, Lin JP, Huang SP. (2014, Apr). Medullary sponge kidney on retrograde pyelography. Chonnam Med J., 50(1):21-2. 本人為通訊作者.
57. Lin VC1, Huang CY, Lee YC, Yu CC, Chang TY, Lu TL, Huang SP, Bao BY. (2014, Apr). Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients. Arch Toxicol., 88(4):901-11. NSC 100- 2314-B-039-009-MY3. 本人為通訊作者.
58. Yu CC, Lin VC, Huang CY, Liu CC, Wang JS, Wu TT, Pu YS, Huang CH, Huang CN, Huang SP*, Bao BY*. (2013, Dec). Prognostic Significance of Cyclin D1 Polymorphisms on Prostate-Specific Antigen Recurrence After Radical Prostatectomy. Ann Surg Oncol. , 20 Suppl 3:492-9. 本人為通訊作者.
59. Huang SP, Lin VC, Lee YC, Yu CC, Huang CY, Chang TY, Lee HZ, Juang SH, Lu TL, Bao BY. (2013, Nov). Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients. . Eur J Cancer., 49(17):3729-37.NSC 99-2314-B-037-018-MY3. 本人為第一作者.
60. Huang TY1, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS. (2013, Oct). Pituitary apoplexy induced by Gonadotropin- releasing hormone agonists for treating prostate cancer-report of first Asian case. World J Surg Oncol., 11:254.
61. Cheng KH, Huang SP, Huang CN, Lee YC, Chu CS, Chang CF, Lai WT, Liu CC. (2013, Mar). The impact of estradiol and 1,25(OH)2D3 on metabolic syndrome in middle-aged Taiwanese males. PLoS One., 8(3):e60295.
62. Chang CF, Pao JB, Yu CC, Huang CY, Huang SP, Yang YP, Huang CN, Chang TY, You BJ, Lee HZ, Hour TC, Bao BY. (2013, Feb). Common Variants in IGF1 Pathway Genes and Clinical Outcomes After Radical Prostatectomy. Ann Surg Oncol., 20(7):2446-52.
63. Yu CC, Huang SP, Lee YC, Huang CY, Liu CC, Hour TC, Huang CN, You BJ, Chang TY, Huang CH, Bao BY. (2013, Jan). Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS One., 8(1):e54627.
JENG-HSIEN YEN
|
◎聯絡方式◎
|
|
連絡電話07-312-1101 ext. 6088
電子信箱 jehsye@kmu.edu.tw
辦公位置：附設醫院啟川大樓
|
|
|
◎學歷◎
|
|
1976/08- 1983/06 高雄醫學院醫學系學士
1985/08- 1988/07 高雄醫學院醫學研究所碩士
1989/08- 1996/01 高雄醫學院醫學研究所博士
|
|
◎現職◎
|
|
高雄醫學大學 醫學院臨床醫學研究所 教授
高雄醫學大學附設中和紀念醫院 免疫風濕科 主任/主治醫師
|
|
◎經歷◎
|
|
1987/08迄今 高醫附設醫院過敏免疫風濕內科主治醫師
1997-1998 Mayo Clinic 博士後研究員
2002 Mayo Clinic
2002 - 2005 高雄醫學大學醫學系 教授
2003
2004 - 2012 高雄醫學大學附設醫院臨床教育訓練部主任
2004 - 2009 高雄醫學大學附設醫院一般醫學內科主任
2004 - 2010
2005 - 2015 高雄醫學大學醫學研究所教授
2006 - 2009 高雄醫學大學
2007 - 2009 高雄醫學大學附設醫院教師培育中心主任
2009 - 2010 高醫附設醫院內科部主任
2009 - 2015 高醫附設醫院過敏免疫風濕內科主任
2012 - 迄今高雄醫學科學雜誌編輯
2012 - 2017高雄醫學大學醫學院 院長
2013 - 2014 高醫附設醫院副院長
2014 - 迄今中山大學生物醫學研究所合聘教授
2015 - 高雄醫學大學臨床醫學研究所教授
2015 - 教育部醫學教育委員會委員
|
|
◎專長領域◎
|
|
免疫風濕疾病、風濕病學、免疫遺傳學、臨床免疫學
|
|
◎研究發表◎
|
|
1. Yuan-Zhao Lin, Ruei-Nian Li, Chia-Hui Lin, Tsan-Teng Ou, Cheng-Chin Wu, Wen-Chan Tsai, Hong-Wen Liu, Jeng-Hsien Yen*. Association of OSMR Gene Polymorphisms with Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients. Autoimmunity 2014 Feb; 47(1): 23-6.
2. Chen-Ching Wu, Shun-Jen Chang*, Jeng-Hsien Yen*. Gout independently
contributed to occurrence of impotence in a national outpatient study. Gout and Hyperuricemia. 2014; 1(1):16-20.
3. Wan-Yu Sung, Pei-Pei Chen, Chia-Chun Tseng, Chen-Ching Wu, Tsan-Teng Ou, Wen-Chan Tsai, Jeng-Hsien Yen*. Anti-SmD and anti-Sm antibodies in the diagnosis of systemic lupus erythematosus. Fomosan J Rheumatol 2014; 28: 11-16.
4. Yen JH, Chang CM, Hsu YW, Lee CH, Wu MS, Hwang DY, Chen BK, Liao
H, Wu M, Chang WC*. A Polymorphism of ORAI1 rs7135617, Is Associated with Susceptibility to Rheumatoid Arthritis. Mediaors Inflamm. 2014; 2014:834831.
5. Liu HW, Lin HL, Yen JH, Tsai WC, Chiou SS, Chang JG, Ou TT, Wu CC, Chao NC. Demethylation within the proximal promoter region of human estrogen receptor alpha gene correlates with its enhanced expression: Implications for female bias in lupus. Mol Immunol. 2014 May 23;61(1): 28-37.
6. Chen CJ, Yen JH*, Chang SJ*. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014; 43(5): 385-90.
7. Andrew S Koenig · Karel Pavelka · Ruben Burgos-Vargas · Pedro Miranda · Renato Guzman · Jeng-Hsien Yen · Mustafa Al Izzi · Zoltan Szekanecz · Boxiong Tang · Annette Szumski. Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. Int J Clin Rheumatol 2014; 9(5):415-30.
8. Chia-Chun Tseng, Jeng-Hsien Yen, Wen Chan Tsai, Tsan-Teng Ou, Cheng-Chin Wu, Wan-Yu Sung, Ming-Chia Hsieh and Shun-Jen Chang*. Increased incidence of Sjogren’s syndrome in systemic sclerosis: A nationwide population study. Autoimmunity. 2015; 48(7): 438-44.
9. Yu-Chin Lin, Hui-Wen Chou, Wen-Chan Tsai, Jeng-Hsien Yen, Shun-Jen Chang, Yi-Chine Lin*. The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study. Clin Rheumatol. 2015; 34(7): 1195-202.
10. Chun-Yu Lin, Tun-Chieh Chen, Chia-Yen Dai, Ming-Lung Yu, Po-Liang Lu, Jeng-Hsien Yen, Yen-Hsu Chen*. Serological investigation to identify risk factors for post-flood infectious diseases: a longitudinal survey among people displaced by Typhoon Morakot in Taiwan. BMJ Open. 2015 May 14;5(5):e007008.
11. Wen-Chan Tsai, Tsan-Teng Ou, Jeng-Hsien Yen, Cheng-Cing Wu, Yi-Ching Tung*. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015 May 13;10(5): e0126347.
12. Tseng CC, Yen JH*, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Chang SJ*. Reduced incidence of Crohn's disease in systemic sclerosis: a nationwide population study. BMC Musculoskelet Disord. 2015 Sep 14; 16: 251. doi: 10.1186/s12891-015-0693-0
13. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. The association between systemic sclerosis and Behcet’s disease: a nationwide cohort study. Formosan J Rheumatol 2015; 29 (2): 1-9.
14. Kuo-Shu Chen, Kuang-Hui Yu, Chih-Sheng Chu, Chung-Ming Huang, Chrong-Reen Wang, Chia-Tse Weng, Chia-Li Yu, Song-Chou Hsieh, Jer-Chia Tsai, Wen-Ter Lai, Wen-Chan Tsai, Guang-Dar Yin, Tsan-Teng Ou, Kai-Hung Cheng, Jeng-Hsien Yen, Teh-Ling Liou, Tsung-Hsien Lin, Der-Yuan Chen, Pi-Jung Hsiao, Meng-Yu Weng, Yi-Ming Chen, Chen-Hung Chen, Ming-Fei Liu, Hsueh-Wei Yen, Jia-Jung Lee, Mei-Chuan Kuo, Chen-Ching Wu, Shih-Yuan Hung, Shue-Fen Luo, Ya-Hui Yang, Hui-Ping Chuang, Yi-Chun Chou, Hung-Ting Liao, Chia-Wen Wang, Chun-Lin Huang, Chia-Shuo Chang, Ming-Ta Michael Lee, Pei Chen, Chih-Shung Wong, Chien-Hsiun Chen, Jer-Yuarn Wu, Yuan-Tsong Chen, Chen-Yang Shen For the Taiwan. Allopurinol-SCAR Consortium. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015 Sep 23; 351: h4848. doi: 10.1136/bmj.h4848.
15. Tzu-Jung Fang, Chia-hui Lin, Yuan-Zhao Lin, Ruei-Nian Li, Tsan-Teng Ou, Cheng-Chin Wu, Wen-Chan Tsai and Jeng-Hsien Yen*. F11R mRNA expression and promoter polymorphisms in patients with rheumatoid arthritis. Int. J Rheum Dis 2016; 19(2): 127-33.
16. Fang TJ, Lin YZ, Liu CC, Lin CH, Li RN, Wu CC, Ou TT, Tsai WC, Yen JH*. Methylation and gene expression of histone deacetylases 6 in systemic lupus erythematosus. Int J Rheum Dis. 2016 Oct; 19(10): 968-9. doi: 10.1111/1756-185X.12783.
17. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study. Joint Bone Spine 2016 May; 83(3): 307-13. doi: 10.1016/j.jbspin.2015.06.017..
18. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Increased incidence of multiple sclerosis in systemic sclerosis: A nationwide cohort study. Preventive Medicine 2016 Mar; 84: 6-11. doi: 10.1016/j.ypmed.2015.12.006..
19. Tai-Ming Ko, Chang-Youh Tsai, Shih-Yang Chen, Ke LY†, Chan HC†, Chen CC, Lu J, Marathe GK, Chu CS, Chan HC, Wang CY, Tung YC, McIntyre TM, Yen JH*, Chen CH*. Enhanced Sphingomyelinase Activity Contributes to the Apoptotic Capacity of Electronegative Low-Density Lipoprotein. Journal of Medicinal Chemistry 2016 Feb 11; 59(3): 1032-40. doi: 10.1021/acs.jmedchem.5b01534.
20. Chia-Chun Tseng, Shun-Jen Chang, Wei-Ting Liao, Ya-Ting Chan, Wen-Chan Tsai, Tsan-Teng Ou, Cheng-Chin Wu, Wan-Yu Sung, Ming-Chia Hsieh, Jeng-Hsien Yen*. Increased Cumulative Incidence of Dermatomyositis in Ulcerative Colitis: a Nationwide Cohort Study. Sci Rep. 2016 Jun 21; 6: 28175. doi: 10.1038/srep28175.
21. Tseng CC, Chang SJ*, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Increased incidence of rheumatoid arthritis in multiple sclerosis: A nationwide cohort study. Medicine (Baltimore). 2016 Jun; 95(26): e3999. doi: 10.1097/
22. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Reply to the comment of Ursini et al. "Retrospective analysis of type 2 diabetes. Prevalence in a systemic sclerosis cohort from southern Italy". Joint Bone Spine. 2016 Oct; 83(5): 613. doi: 10.1016/j.jbspin.2016.07.011.
23. Wong TH, Chen HA, Gau RJ, Yen JH, Suen JL. Heme xygenase-1-Expressing Dendritic Cells Promote Foxp3+ Regulatory T Cell Differentiation and Induce Less Severe Airway Inflammation in Murine Models. PLoS One. 2016 Dec 29; 11(12): e0168919.
24. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: A Nationwide Cohort Study. Arthritis Care Res (Hoboken). 2017 Aug; 69(8): 1231-7. doi: 10.1002/acr.23119.
25. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Sex differential association of dermatomyositis with Sjögren syndrome. CMAJ. 2017 Feb 6; 189 (5): E187-E193. doi: 10.1503/cmaj.160783.
26. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Incidence réduite des diabètes de type 1 et de type 2 dans la sclérodermie systémique : étude d’une cohorte nationale. Revue du rheumatism. 2017 May; 84(3): 213- 20.
27. Chen Yi-Jing and Yen Jeng-Hsien*. Release of Tumor Necrosis Factor Alpha and Interleukin-1 Beta from THP-1 Cells Infected with Candida parapsilosis. Jundishapur Journal of Microbiology. 2017 Apr ; 10(4): e39155. doi: 10.5812/jjm.39155.
28. Chung-Jen Chen, Chia-Chun Tseng, Jeng-Hsien Yen, Jan-Gowth Chang, Wen-Cheng Chou, Hou-Wei Chu, Shun-Jen Chang, Wei-Ting Liao*. ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study. Sci Rep. 2018 Feb 16; 8(1): 3137. doi: 10.1038/s41598-018- 21425-7.
29. Wong TH, Lee CL, Su HH, Lee CL, Wu CC, Wang CC, Sheu CC, Lai RS, Leung SY, Lin CC, Wei YF, Wang CJ, Lin YC, Chen HL, Huang MS, Yen JH, Huang SK, Suen JL. A prominent air pollutant, Indeno[1,2,3-cd]pyrene, enhances allergic lung inflammation via aryl hydrocarbon receptor. Sci Rep. 2018 Mar 26; 8(1): 5198. doi: 10.1038/s41598-018-23542-9
30. Tzu-Ching Huang, Wen-Tsan Chang, Yu-Chen Hu, Bau-Shan Hsieh, Hsiao-Ling Cheng, Jeng-Hsien Yen, Pu-Rong Chiu* and Kee-Lung Chang*. Zinc Protects Articular Chondrocytes through Changes in Nrf2-Mediated Antioxidants, Cytokines and Matrix Metalloproteinases. Nutrients 2018; 10(4): 471; doi:10.3390/nu10040471 (registering DOI)
31. Tseng CC, Chen CJ, Yen JH, Huang HY, Chang JG, Chang SJ, Liao WT*. Next-generation sequencing profiling of mitochondrial genomes in gout. Arthritis Res Ther 2018 Jul 6; 20(1): 137. doi: 10.1186/s13075-018-1637-5.
32. Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, Hsieh MC, Yen JH*. Reply to “Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: comment on the article by Tseng et al. Arthritis Care Res (Hoboken). 2018 Jul; 70(7): 1120. doi: 10.1002/acr.23432
33. Hung YH, Lee YH, Chen PP, Lin YZ, Lin CH, Yen JH*. Role of Salivary Immune Parameters in Patients With Primary Sjögren's Syndrome. Ann Lab Med. 2019 Jan; 39(1): 76-80. doi: 10.3343/alm.2019.39.1.76.
34. Tseng CC, Lin YC, Lin CH, Li RN, Tsai WC, Ou TT, Wu CC, Sung WY, Yen JH*. Genetic and Epigenetic Alteration of the Programmed Cell Death 1 (PDCD1) in Rheumatoid Arthritis. Eur J Clin Invest. 2019 Feb 27: e13094. doi: 10.1111/eci.13094.
35. Li RN, Lin YZ, Pan YC, Lin CH, Tseng CC, Sung WY, Wu CC, Ou TT, Tsai WC, Yen JH*. GADD45a and GADD45b Genes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients. J Clin Med. 2019 Jun 5;8(6). pii: E801.
36. Tseng CC, Wu LY, Tsai WC, Ou TT, Wu CC, Sung WY, Kuo PL, Yen JH*.
Differential Expression Profiles of the Transcriptome and miRNA Interactome in Synovial Fibroblasts of Rheumatoid Arthritis Revealed by Next Generation Sequencing. Diagnostics (Basel). 2019 Aug 18;9(3). pii: E98
37. Tseng CC, Lin YZ, Lin CH, Li RN, Yen CY, Chan HC, Tsai WC, Ou TT, Wu CC, Sung WY, Yen JH. Next-Generation Sequencing Profiles of the
Methylome and Transcriptome in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis. J Clin Med. 2019 Aug 22;8(9). pii: E1284.
|
|
JAW-YUAN WANG
王照元教授Jaw-Yuan Wang
· 連絡電話：07-312-1101 ext. 5575
· 電子信箱： cy614112@ms14.hinet.net; jayuwa@cc.kmu.edu.tw
· 辦公位置：醫學研究部、啟川18ES醫局
專長
腫瘤外科、消化外科、大腸直腸外科、分子生物學、營養學
研究領域
學歷
高雄醫學大學博士1999-2003
高雄醫學大學碩士1993-1996
高雄醫學院學士1982-1989
高雄醫學大學附設中和紀念醫院副院長
高雄醫學大學附設中和紀念醫院大腸直腸外科主任
高雄醫學大學附設中和紀念醫院人體生物資料庫主任
高雄醫學大學醫學院臨床醫學研究所教授
高雄醫學大學醫學院外科學教授
高雄醫學大學醫學研究所碩士班主任2009/08~2012/07
高雄醫學大學醫學系實驗外科學主任2009/08~2012/07
高雄醫學大學醫學院研發組組長2006/08~2009/07
高雄醫學大學基因體醫學研究中心學術推動組組長2002/02~2006/07
高雄醫學大學臨床醫學研究所所長2012/08~2014/07
|
序號
|
計畫名稱及編號
|
補助單位
|
執行期限
|
計劃內
擔任之工作
|
|
1
|
Development of the MMP-2-activated pro-aEGFR/HER2 Ab for selective tumor therapy and reducing side-effects
|
|
2014/05
-present
|
PI
|
|
2
|
Biomarkers for the early diagnosis, prediction, prognosis for colorectal cancers
|
|
2013/01
|
PI
|
|
3
|
The prevention early detection/diagnosis, and personalized Therapy of colorectal cancer
|
|
2014/01
-present
|
PI
|
|
4
|
Integration of tailored therapy and mini-invasive surgery for colorectal cancer
|
Kaohsiung Medical University Hospital
|
2014/11
-2015/7
|
PI
|
|
5
|
Da Vinci Minimally invasive surgery
|
Kaohsiung Medical University Hospital
|
2014/10
-2015/07
|
PI
|
|
6
|
Integration of tailored therapy and mini-invasive surgery for colorectal cancer
|
Kaohsiung Medical University Hospital
|
2015/8
-2016/7
|
PI
|
|
7
|
Prospective analysis of UGT1A promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI as the first-line setting
|
Kaohsiung Medical University Hospital
|
2015/08
2016/07
|
PI
|
|
8
|
To develop the protease specific (perforin-Grazyme) for targeting colon cancer therapy
|
Kaohsiung Medical University
|
2015/09
2016/07
|
PI
|
|
9
|
Da Vinci Minimally invasive surgery
|
Kaohsiung Medical University Hospital
|
2015/08
-2016/07
|
PI
|
|
10
|
Integration of tailored therapy and mini-invasive surgery for colorectal cancer
|
Kaohsiung Medical University Hospital
|
2016/8
-present
|
PI
|
|
11
|
Prospective analysis of UGT1A promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI as the first-line setting
|
Kaohsiung Medical University Hospital
|
2016/08
-present
|
PI
|
|
12
|
Da Vinci Minimally invasive surgery
|
Kaohsiung Medical University Hospital
|
2016/08
-present
|
PI
|
產學合作計畫
|
序號
|
計劃名稱
|
委託機構
|
執行期限
|
計劃內
擔任之工作
|
| |
Hi-Q 小分子褐藻醣膠於大腸直腸癌上的輔助使用
Hi-Q Marine Biotech International Ltd
|
中華海洋生技股份有限公司
|
103/07/01-105/06/30
|
分項計畫主持人
|
| |
Hi-Q Fucoidam 與Erbitux於大腸直腸癌治療的協同效果
|
中華海洋生技股份有限公司
|
105/10/1-107/9/30
|
分項計畫主持人
|
|
年度
|
國別
|
專利/技轉名稱
|
成果產出歸屬計畫
(專屬或非專屬授權)
|
專利證
書號碼
|
發明人
|
專利期限
|
|
96
|
中華
民國
|
用於診斷大腸直腸癌之組合物
|
90-2317-B-037-075
|
發明第I278519號
|
林綉茹
王照元
|
2007/04/00 ~
2023/12/00
|
|
97
|
美國
|
用於診斷大腸直腸癌之組合物
|
90-2317-B-037-075
|
7575928
|
林綉茹
王照元
|
2009/08/00~
2028/08/00
|
|
100
|
歐盟
|
用於診斷人類大腸直腸癌的基因群
|
90-2317-B-037-075
|
EP1564302
|
林綉茹
王照元
|
2011/10/00~
2030/09/
|
|
100
|
日本
|
用於診斷人類大腸直腸癌的基因群
|
90-2317-B-037-075
|
2004-044186
|
林綉茹
王照元
|
2011/10/00~
2030/09/00
|
|
104
|
中華
民國
|
用於抑制結腸直腸癌及子宮上皮癌生長轉移之醫藥組合物
|
100-2320-B-037-002
|
發明第I504404號
|
張偉嶠
王照元
王堉璿
卓夙航
|
2015/10/21
~
2030/07/21
|
|
102
|
美國
|
以微小去氧核醣核酸為基礎用於抗大腸直腸癌及大腸直
|
99-2320-B-037-014-MY3
|
US8,420,618
|
卓夙航
王照元
楊以屏
蔡祥麟
|
2013/04/16
~
2020/10/16
|
|
104
|
美國
|
以微小去氧核醣核酸為基礎用於抗大腸直腸癌及大腸直
|
99-2320-B-037-014-MY3
|
US8,940,480
|
卓夙航
王照元
楊以屏
蔡祥麟
|
2015/01/27
~
2022/10/16
|
|
105
|
中華
民國
|
以微小去氧核醣核酸為基礎用於抗大腸直腸癌及大腸直
|
99-2320-B-037-014-MY3
|
發明第I546075號
|
卓夙航
王照元
楊以屏
蔡祥麟
|
2016/08/21
~
2031/06/22
|
|
105
|
中華
民國
|
大腸癌的檢測方法及其應用
|
102-2628-B-037-002-MY3
|
發明第I521207號
|
王照元
郭柏麟
甘蓉瑜
|
2016/2/11
~
2034/12/30
|
|
105
|
中華
民國
|
衛教輔助裝置
|
|
發明第M523462號
|
王照元
孫麗珠
石英鈴
|
2016/6/11
~
2026/1/11
|
|
104
|
中華
民國
|
非類固醇消炎止痛藥物之用途
|
|
申請中
|
張偉嶠
王照元
黃旼儀
王堉璿
|
|
期刊論文發表(近五年)
1. Chuang YP, Wang JY, Jao SW, Wu CC, Chen JH, Hsiao KH, Lin CY, Chen SH, Su SY, Chen YJ, Chen YT, Wu DC, Li LH. Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression. Oncotarget. 2016. MOST104-2325-B-037-001, MOHW105- TDU-B-212-134007, Health and welfare surcharge of tobacco products, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
2. Yang IP, Tsai HL,Huang CW, Lu CY, Miao ZF, Chang SF, Juo SH, Wang JY*. High Blood Sugar Levels Significantly Impact the Prognosis of Colorectal Cancer Patients through Down-regulation of MicroRNA-16 by Targeting Myb and VEGFR2. Oncotarget. 2016 Feb 25. MOST103-2314-B-037-010-MY3,MOHW105-TDU-B-212-134005,Health and welfare surcharge of tobacco products, KMUH102-2M46, KMUH103-3M39, KMU-TP104C00, KMU-TP104C01, KMU-TP104C02, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Oncology, IF: 6.359, Ranking: 21/211, 2014 JCR).
3. Yang IP, Tsai HL,Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, Wang JY*. Development of a Deregulating microRNA Panel for the Detection of Early Relapse in Postoperative Colorectal Cancer Patients. J Transl Med 2016 Apr 29;14(1):108. (MOHW105-TDU-B-212-134007), (KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP104A11, KMU-PT10422, KMU-DK105001); (MOST104-2325-B-037-001); (KMUH103-3M39; KMUH103-3M58; KMUH104-4M51); and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Medicine, Research & Experimental, IF: 3.930, Ranking: 26/123, 2014 JCR).
4. Kan JY, Yen MC, Wang JY, Wu DC, Chiu YJ, Ho YW, Kuo PL. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget. 2016 May 2.
5. Su WC, Tsai HL, Yeh YS, Huang CW, Chen FM, Wang JY*. Successful Management of Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Three Case Reports and Literature Review. J Soc Colon Rectal Surgeon (Taiwan) 2016;27:83-89.
6. Chen YT, Tsao SC, Tsai HP, Wang JY, Chai CY. Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. J Clin Pathol. 2016 Apr 22.
7. Huang CW, Yeh YS, Ma CJ, Tsai HL, Chen CW, Huang MY, Lu CY, Wu JY, Wang JY*. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as a First-Line Treatment. Chemotherapy (Accepted in 2016). MOST104-2325-B-037-001); (MOHW 105-TDU-B-212-134007), (KMUH104-4M29, KMUH104-4R19, KMUH-S10415, KMUH-S10418,); (KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP103H10, KMU-TP103H11, KMU-PT104002, KMU-DK105001, D08-00005-10401); (KMU-TP104A11), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
8. Huang CW, Yeh YS, Su WC,Tsai HL, Choy TK, Huang MY, Huang CM, Wu IC, Hu HM, Hsu WH, Su YC, Wang JY*. Robotic Surgery with High Dissection and Low Ligation Technique for Consecutive Patients with Rectal Cancer Following Preoperative Concurrent Chemoradiotherapy. Int J Colorectal Dis 2016 Jun;31(6):1169-77. MOHW105-TDU-B-212-134007, KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP104A11, KMU-PT10422, KMU-DK105001; MOST104-2325-B-037-001; KMUH103-3M39; KMUH103-3M58; KMUH104-4M51; and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Surgery, IF: 2.449, Ranking: 55/198, 2014 JCR).
9. Tsai HL, Huang CW, Chen CW, Yeh YS, Ma CJ, Wang JY*. Survival in Resected Stage II Colorectal Cancer Is Dependent on Tumor Depth, Vascular Invasion, Postoperative CEA Level, and The Number of Examined Lymph Nodes. World J Surg 2016 Apr;40(4):1002-9. (Category: Surgery, IF: 2.642, Ranking: 47/198, 2014 JCR). MOST104-2325-B-037-001; MOHW 104-TDU-B-212-124-003, KMUH100-OM16, KMUH103-3R16, KMUHS10304,KMUHS10305; KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, KMU-TP104A11); and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
10. Chen YT, Tsao SC, Tsai HP, Wang JY, Chai CY. The X-linked inhibitor of apoptosis protein is an independent prognostic marker for rectal adenocarcinoma after preoperative chemoradiotherapy. Virchows Arch 2016 Feb 25. (Category: Pathology, IF: 2.651, Ranking: 23/76, 2014 JCR).
11. Yeh YS, Tsai HL, Huang CW, Wang JH, Lin YW, Tang HC, Sung YC, Wu CC, Lu CY, Wang JY*. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials 2016 Jan 25;17(1):46. MOST103-2314-B-037-010-MY3,MOHW105-TDU-B-212-134005,Health and welfare surcharge of tobacco products, KMUH102-2M46, KMUH103-3M39, KMU-TP104C00, KMU-TP104C01, KMU-TP104C02. (Category: Medicine, Research & Experimental, IF: 1.731, Ranking: 81/123, 2014 JCR).
12. Huang MY, Huang CM, Tsai HL, Huang CW, Hsieh HM, Yeh YS, Wu JY, Wang WM, Wang JY*. Comparison of adjuvant FOLFOX4 chemotherapy versus oral UFT/LV following adjuvant FOLFOX4 chemotherapy in stage III colon cancer patients after radical resection. Oncology Letters 2015 (Accepted), MOST103-2314-B-037-010-MY3, MOHW 104-TDU-B-212-124-003,KMUH103-3M03, KMUHS10418,KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11. (Category: Oncology, IF: 1.554, Ranking: 173/211, 2014 JCR).
13. Lu CY, Huang CW, Wu IC, Tsai HL, Ma CJ, Yeh YS, Chang SF, Huang ML, Wang JY*. Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting. Transl Oncol 2015 Dec;8(6):474-9. MOST103-2314-B-037-010-MY3, MOHW 104-TDU-B-212-124-003, KMUH102-2M46, KMUH103-3M39, KMU-TP104C00, KMU-TP104C01, KMU-TP104C02. (Category: Oncology, IF: 2.884, Ranking: 105/211, 2014 JCR).
14. Wang JY, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, He H, Krishna N, Chiu SJ, Lin S, Yang S, Chang WC*. STIM1 Overexpression Promotes Colorectal Cancer Progression, Cell Motility and COX-2 Expression. Oncogene 2015 Aug 13;34(33):4358-67. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, KMU-TP103C03. SCI. (Category: Oncology, IF: 8.459, Ranking: 13/211, 2014 JCR).
15. Chen KC, Liao YC, Wang JY, Lin YC, Chen CH, Juo SH. Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210. Oncotarget 2015 Sep 15;6(27):24105-18. SCI. (Category: Oncology, IF: 6.359, Ranking: 21/211, 2014 JCR).
16. Huang CC, Kuo KK, Cheng TC, Chuang CH, Kao CH, Hsieh YC, Cheng KH, Wang JY, Cheng CM, Chen CS, Cheng TL. Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. PLoS One. 2015 Jul 17;10(7):e0133470. SCI. (Category: Multidisciplinary Sciences, IF: 3.234, Ranking: 8/56, 2014 JCR).
17. Huang CW, Tsai HL, Huang MY, Huang CM, Yeh YS, Ma CJ, Wang JY*. Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer. World J Surg Oncol. 2015 Aug 28;13:257. SCI. (Category: Surgery, IF=1.408; Ranking: 107/198, 2014 JCR).
18. Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, Wang JY*. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. PLoS One. 2015 Apr 28;10(4):e0123973. SCI. (Category: Multidisciplinary Sciences, IF: 3.234, Ranking: 8/56, 2014 JCR).
19. Yeh YS, Huang YH, Lin HC, Shih YL, Lu CY, Wang JY*. J Gastrointest Dig Syst S Long-Term Recurrent Liposarcoma of the Mediastinum with Gastric Metastasis: A Case Report. 2015;S13:1.
20. Huang CW, Yeh YS, Ma CJ, Choy TK, Huang CM, Hsu WH, Wang JY*. Robotic colorectal surgery for laparoscopic surgeons with limited experience: Preliminary experiences for 40 consecutive cases at a single medical center. BMC Surg 2015 Jun 18;15:73.MOST103-2325-B-037-005, MOHW103-TD-B-111-05, KMUH103-3R16, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Surgery, IF=1.397; Ranking: 108/198, 2014 JCR).
21. Kan JY, Wu DC, Yu FJ, Wu CY, Ho YW, Chiu YJ, Jian SF, Hung JY, Wang JY*, Kuo PL*. Chemokine (C-C motif) ligand 5 is involved in tumor-associated dendritic cell-mediated colon cancer progression through noncoding RNA MALAT-1. J Cell Physiology 2015 Aug;230:1883-94. SCI. (Category: Physiology, IF=3.839; Ranking: 15/83, 2014 JCR). (Equally contributed corresponding author).
22. Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY*. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol 2015 Feb 1;8(2):1900-10. SCI. (Category: Pathology, IF=1.895; Ranking: 40/75, 2014 JCR).
23. Lee YC, Yin TC, Chen YT, Chai CY, Wang JY, Liu MC, Lin YC, Kan JY. High Expression of Phospho-H2AX Predicts a Poor Prognosis in Colorectal Cancer. Anticancer Res 2015 Apr;35:2447-53. SCI. (Category: Oncology, IF: 1.826, Ranking: 162/211, 2014 JCR).
24. Huang MY, Lin CH, Huang CM, Tsai HL, Huang CW, Yeh YS, Chai CY, Wang JY*. Relationships between SMAD3 Expression and Preoperative Fluoropyrimidine-Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients. World J Surg 2015 May;39(5):1257-67. MOST103-2325-B-037-005 and MOHW 104-TDU-B-212-124-003, KMUH103-3R16, KMUHS10304, KMUHS10305, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Surgery, IF=2.642; Ranking: 47/198, 2014 JCR).
25. Ma CJ, Wu JM, Tsai HL, Huang CW, Lu CY, Sun LC, Shih YL, Chen CW, Chuang JF, Wu MH, Wang MY, Lin MS, Wang JY*. Prospective Double-Blind Randomized Study on the Efficacy and Safety of an n-3 Fatty Acid enriched intravenous fat emulsion in Postsurgical Gastric and Colorectal Cancer Patients. Nutr J 2015 Jan 21;14:9. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, KMU-TP103C00. SCI. (Category: Nutrition & Dietetics, IF=2.597; Ranking: 36/77, 2014 JCR).
26. Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL*. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials. 2014 Dec;35(37):9930-40 SCI. (Category: Materials Science, Biomaterials, IF: 8.312, Ranking: 1/32, 2013 JCR). (Equally contributed first author). MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
27. Chuang KH, Kao CH, Roffler SR, Lu SJ, Cheng TC, Wang YM, Chuang CH, Hsieh YC, Wang YT, Wang JY, Weng KY, Cheng TL*. Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules 2014.MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: in Polymer Science, IF=5.927, Ranking: 3/82, 2013 JCR).
28. Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL. PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy. Mol Cancer Ther 2014 Dec;13(12):2852-63. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI (Category: Oncology, IF: 6.107, Ranking: 23/202, 2013 JCR).
29. Li CF, He HL, Wang JY, Huang HY, Wu TF, Hsing CH, Lee SW, Lee HH, Fang JL, Huang WT, Chen SH. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014 Dec;67(12):1056-61. MOHW103-TD-B-111-05. SCI.
30. Tsai PC, Huang SW, Tsai HL, Ma CJ, Hou MF, Wang YS, Juo SH, Wang JY*. The association between DNA copy number aberrations at chromosome 5q22 and gastric cancer. PLoS One 2014 Sep 11;9(9):e106624. KMUH98-8I04, KMUH98-8G05, KMUH99-9R03, MOHW103-TD-B-111-05, NSC 99-2320-B-037-014-MY3, NSC 94-2314B037-104. SCI. (Category: Multidisciplinary Sciences, IF: 3.534, Ranking: 8/55, 2013 JCR).
31. Cheng DE, Tsai YM, Hsu YL, Hou MF, Tsai EM, Wang JY, Kan JY, Kuo PL. Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation. Oncol Lett 2014 Aug;8(2):620-626. SCI.
32. Cheng AL, Li J, Vaid AK, Ma B, Teh CS, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes Jr. G, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW. Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus. Clinical Colorectal Cancer 2014 Sep;13(3):145-55. SCI
33. Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY*. FOLFIRI and Regorafenib Combination Therapy with Dose Escalation of Irinotecan as Fourth-Line Treatment for Metastatic Colon Cancer Patients According to Uridine Diphosphate-Glucuronosyltransferase 1A1 Genotyping. OncoTargets_and_Therapy 2014 Nov 21;7:2143-2146. MOHW103-TD-B-111-05; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan; NSC 99-2320-B-037-014-MY3; KMUH98-8G64, KMUH102-2R18. SCI
34. Huang MY, Liu HC, Yen LC, Chang JY, Huang JJ, Wang JY, Lin SR. Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip. Tumour Biol. 2014 Oct;35(10):9639-47. (MOHW103-TD-B-111-05), the Kaohsiung Medical University Hospital (KMUH101-1M66, KMUH102-2M46), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
35. He HL, Lee YE, Shiue YL, Lee SW, Lin LC, Chen TJ, Wu TF, Hsing CH, Huang HY, Wang JY, Li CF. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. J Surg Oncol 2014 Aug 22. 110(8):1002-10. SCI.
36. Huang CM,Huang CW, Huang MY,Lin CH,Chen CF,Yeh YS,Ma CJ, Huang CJ, Wang JY*. Co-existence of perineural invasion and lymph node metastases is a poor prognostic factor in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by radical resection and adjuvant chemotherapy. Med Princ Pract 2014;23(5):465-70. MOHW103-TD-B-111-05, KMUH100-0M49, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
37. Lu CY, Huang CW, Hu HM, Tsai HL, Huang CM, Yu FJ, Huang MY, Chang SF, Huang ML*, Wang JY*. The Prognostic Advantage of Irinotecan Dose Escalation According to UGT1A1 Genotyping in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in a First-line Setting. Transl Res 2014 Aug;164(2):169-76. MOHW103-TD-B-111-05, KMUH96-6G03 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Medical Laboratory Technology, IF: 5.030, Ranking: 2/30, 2014 JCR).
38. Huang MY, Chen CF, Huang CM, Tsai HL, Yeh YS, Ma CJ, Wu CH, Lu CY, Chai CY, Huang CJ, Wang JY*. Helical Tomotherapy Combined with Capecitabine in The Preoperative Treatment of Locally Advanced Rectal Cancer. Biomed Res Int 2014;2014:352083.MOHW103-TD-B-111-05, KMUH99-9M07, KMUH101-1M66, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
39. Huang MY, Liu HC, Yen LC, Chang JY, Huang JJ, Wang JY, Hsiao CP, Lin SR. Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. J Transl Med 2014, 12:147. NSC 99-2320-B-242-002-MY3, MOHW103-TD-B-111-5), KMUH101-1 M66, KMUH102-2 M46, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Medicine, Research & Experimental, IF: 3.991, Ranking: 24/122, 2013 JCR).
40. Sun LC, Tai YY, Liao SM, Lin TY, Shih YL, Chang SF, Huang CW, Chan HM, Huang CJ, Wang JY*. Clinical Characteristics of Second Primary Cancer in Colorectal Cancer Patients: the impact of colorectal cancer or other second cancer occurring first. World J Surg Oncol 2014;Mar 28;12(1):73. MOHW103-TD-B-111-05, KMUH100-OR16 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
41. Tsai YT, Chang CM, Wang JY, Hou MF, Wang JM, Shiurba R, Chang WC, Chang WC*. Function of DNA methyltransferase 3a in lead (Pb2+ )-Induced Cyclooxygenase-2 gene. Environ Toxicol. 2014 Mar 17. SCI.
42. Tsai HL, Lin CH, Cheng YL, Huang CW, Wang JY*. Rectal Carcinoma in a Young Female Patient with Peutz-Jeghers Syndrome: A Case Report. Med Princ Pract. 2014;23(1):89-91. SCI.
43. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. SCI.
44. Su CH, Yu FJ, Tsai HL, Wang JY*. Endoscopic Closure of Colonic Fistulas in Colon Cancer Patients Using a Combination of Hemoclips and Endoloops: Two Case Reports. Techniques in Coloproctology. 2014 Feb;18(2):205-8. DOH101-TD-C-111-002. SCI.
45. Wu JY, Cheng CC, Wang JY, Wu DC, Hsieh JS, Lee SC, Wang WM. Discovery of tumor markers for gastric cancer by proteomics. PLoS One. 2014 Jan 3;9(1):e84158. SCI.
46. Ma YS, Yang IP, Tsai HL, Huang CW, Juo SH, Wang JY*. High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells. DNA Cell Biol 2014 Feb;33(2):64-72.DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
47. Yeh YS, Huang ML, Chang SF, Chen CF, Hu HM, Wang JY*. FOLFIRI Combined with Bevacizumab as the First-line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping. Med Princ Pract 2014;23(5):478-81. DOH102-TD-C-111-002, KMUH96-6G03 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
48. Huang MY, Wu CH, Chung FY, Huang CM, Huang CW, Tsai HL, Chen CF, Lin SR*, Wang JY*. DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy. Biomed Res Int 2013;2013:931028. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
49. Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY*. The Prognostic Values of EGFR Expression and KRAS Mutation in Patients with Synchronous/Metachronous Metastatic Colorectal Cancer. BMC Cancer. 2013 Dec 13;13(1):599. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
50. Kan JY, Hsu YL, Chen YH, Chen TC, Wang JY*, Kuo PL*. Gemifloxacin, a fluoroquinolone antimicrobial drug, inhibits migration and invasion of human colon cancer cells. Biomed Res Int 2013 Dec 13;13:599. doi: 10.1155/2013/159786. Epub 2013 Dec 10. DOH102-TD-C-111-002. SCI.
51. Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM, Lin IL, Lu CY, Chai CY, Wang JY*. Predictive Value of ERCC1, ERCC2, and XRCC1 Overexpression for Stage III Colorectal Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. J Surg Oncol 2013 Dec;108(7):457-64. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
52. Tsai HL, Yang IP, Huang CW, Ma CJ, Kuo CH, Lu CY, Juo SH, Wang JY*. Clinical significance of miRNA-148a for early relapse of stage II and III colorectal cancer patients following curative resection. Translation Research 2013 Oct;162(4):258-68. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Medical Laboratory Technology, IF: 5.030, Ranking: 2/30, 2014 JCR).
53. Huang MY, Yen LC, Liu HC, Liu PP, Chung FY, Wang JY*, Lin SR*. Significant Overexpression of DVL1 in Taiwanese Colorectal Cancer Patients with Liver Metastasis. Int J Mol Sci 2013 Oct 14;14(10):20492-507. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI..
54. Yang IP, Tsai HL, Juo SH, Huang MY, Hou MF, Wang JY*. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One. 2013 Jun 28;8(6):e66842. NSC99-2320-B-037-014-MY3, KMUH98-8I04, KMUH100-OR16, DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
55. Chan CP, Tsai YT, Chen YL, Hsu YW, Tseng JT, Chuang HY, Shiurba R, Lee MH, Wang JY*, Chang WC*. Pb2+ induces gastrin gene expression by extracellular signal-regulated kinases 1/2 and transcription factor activator protein 1 in human gastric carcinoma cells. Environ Toxicol. 2013 Jun 14. doi: 10.1002/tox.21878. [Epub ahead of print]. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
56. Kao LC, Yang PF, Ma CJ, Huang CW, Chen FM, Chan HM, Huang CJ, Hsieh JS, Wang JY*. The Impact of Metastatic Ratio to Harvested Regional Lymph Nodes on Overall Survival in Patients with Stage III Colorectal Cancer: Focus on Numbers of Lymph Node Harvest Less Than 12. J Soc Colon Rectal Surgeon 2013;24(2):37-42.
57. Wu CH, Chung FY, Chang JY, Wang JY*. Rapid detection of gene expression by a colorectal cancer enzymatic gene chip detection kit. Biomark Genomic Med 2013;5(3):87-91.
58. Huang MY, Chen HC, Yang IP, Tsai HL, Juo SH, Wang JY*. Analysis of gene expression profiles in tumorigenesis/progression of colorectal cancers using GeXP multiplex assay. Cancer Biomark 2013 April;13(4):269-79. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. NSC99-2320-B-037-014-MY3, 100-CCH-KMU-002. SCI.
59. Chen CW, Ma CJ, Shan YS, Yeh YS, Wang JY*. Prospective, Randomized, Controlled Study of Ampicillin/Sulbactam versus Moxifloxacin Monotherapy for the Treatment of Community-Acquired Complicated Intra-Abdominal Infections" in its current form for publication in Surgical Infections. Surg Inf 2013 Aug;14(4):389-96. SCI.
60. Tsai HL, Wang JY*. Predictors of response in locally advanced rectal cancer following concurrent chemoradiotherapy. Biomark Genomic Med 2013;5:8-12. DOH102-TD-C-111-002, Biosignature in Colorectal Cancers, Academia Sinica. Review article.
61. Huang MY, Wang JY*, Lin SR*. CA9 and CHRNB1 were correlated with perineural invasion in Taiwanese colorectal cancer patients. Biomark Genomic Med 2013;5:84-86.
62. Chen CF, Chuang CH Hu C, Wang JY*. Ileus secondary to a retroperitoneal malignant melanoma. Biomark Genomic Med 2013;5(3): 113-6..
63. Chou WW, Chen KC, Wang YS, Wang JY, Liang CL, Juo SH. The role of SIRT1/AKT/ERK pathway in ultraviolet B induced damage on human retinal pigment epithelial cells. Toxicol In Vitro 2013 May 11;27(6):1728-1736. SCI.
64. Ou CH, Kuo FC, Hsu WH, Lu CY, Yu FJ, Kuo CH, Wang JY, Wu MT, Shiea J, Wu DC, Hu HM. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan. J Dig Dis 2013 Sep;14(9):474-83 . SCI.
65. Chen CW, Tsai HL, Yeh YS, Lin HL, Huang CW, Chen CF, Chang YT, Lou YT, Wang JY*. Osteoporosis self-assessment tool for Asians as a simple risk index for identifying poor prognosis in women surgically treated for colorectal cancer. J Surg Res 2013 May;181(2):242-9. KMUH98-8I04 and KMUH99-9M03; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
66. Lin CH, Liu CH, Tsai HL, Wang JY, Tsai HP, Chai CY. Expression of OV-6 in primary colorectal cancer and rectal cancer with preoperative chemoradiotherapy: a clinicopathological study. Histopathology 2013 Apr;62(5):742-51. DOH102-TD-111-002. SCI.
67. Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY*. Circulating Tumor Cells as a Surrogate Marker for Determining Clinical Outcome to mFOLFOX Chemotherapy in Patients with Stage III Colon Cancer. Br J Cancer 2013 Mar 5;108(4):791-7. NSC99-2320-B-037-014-MY3, KMUH98-8I04, DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, 99CM-KMU-02. SCI.
68. Tsai HL, Yang IP, Yang IP, Chai CY, Huang YH, Chen CF, Hou MF, Kuo CH, Juo SH, Wang JY*. Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection. Int J Colorectal Dis 2013 Mar;28(3):415-24. KMUH98-8I04; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
69. Huang MY,Wang JY, Huang ML, Chang HJ, Lin SR. Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. IntJ Mol Sci2013 Feb 19;14(2):4121-34. DOH102-TD-111-002, KMUH100-0M48, ZAFGH 100-05, ZAFGH 101-07, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Equally first author).
70. Tsai HL, Yeh YS, Chang YT, Yang IP, Lin CH, Kuo CH, Juo SH, Wang JY*. Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 2013 Feb;107(2):148-54. KMUH98-8I04; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.
71. Yeh YS, Tsai HL, Ma CJ, Wu DC, Lu CY, Wu IC, Hou MF, Wang JY*. A retrospective study of the safety and efficacy of a first-line treatment with mFOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Chemotherapy 2012;58(5):411-8. SCI. DOH102-TD-C-111-002. SCI.
72. Yang PF, Chen CY, Kao LC, Ma CJ, Chen FM, Chan HM, Huang CJ, Hsieh JS, Wang JY*. Computed Tomography in the Postoperative Surveillance of Stage III Colorectal Cancers Receiving Adjuvant Chemotherapy. J Soc Colon Rectal Surgeon 2012;23(4):144-50.
73. Huang ML, Kan JY, Ma CJ, Huang CW, Chen FM, Chuang CH, Chan HM, Huang CJ, Chang SF, Wen YH, Wang JY*. An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer. Genomic Med Bio Mark Health Sci 2012:4;122-127. DOH102-TD-C-111-002, ZAFGH 101-07, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
74. Yang IP, Tsai HL, Hou MF, Chen KC, Tsai PC, Huang SW, Chou WW, Wang JY*, Suh-Hang Hank Juo*. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis. 2012 Aug;33(8):1522-30.NSC99-2320-B-037-014-MY3; KMUH98-8I04, KMUH100-OR16; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Equally corresponding authors).
75. Chen CW, Chen MJ, Yeh YS, Tsai HL, Chang YT, Lu CY, Shih YL, Sun LC,Wang JY*. Intraoperative anastomotic dye test significantly decrease anastomotic leaks in patients with rectal cancers receiving resection. Techniques in Coloproctology. 2013 Oct;17(5):579-83.DOH101-TD-C-111-002. SCI.
76. Chen YC, Tsai HL, Lin CH, Huang CJ, Wang JY*. Adenosquamous Carcinoma of the Colon: A Case Report. Genomic Med Bio Mark Health Sci 2012;4:103-6.
77. Chang YT, Lee JY, Chiu CS, Wang JY*. Feasibility of Emergency Laparoscopic Colectomy for Children with Acute Colonic Perforations and Fibropurulent Peritonitis. World J Surg 2012 Aug;36(8):1958-62. SCI.
78. Yeh YS, Chen MJ, Tsai HL, Huang MY, Chen CW, Huang YH, Sheen MC, Wang JY*. Transanal inside out rectal resection for ultra-low rectal cancer. J Invest Surg 2012 Dec;25(6):375-80. DOH101-TD-C-111-002. SCI.
79. Lin HL, Chen CW, Lu CY, Sun LS, Shih YL, Chuang JF, Huang YH, Sheen MC, Wang JY*. Elevated Preoperative Blood Urea Nitrogen-to-Creatinine Ratio Increased Mortality in Gastrointestinal Cancer Patients Developing Enteric Fistula. Kaohsiung J Med Sci2012 Aug;28(8):418-22.DOH100-TD-C-111-002. SCI.
80. Kuo TY, His E, Yang IP, Tsai PC, Wang JY*, Suh-Hang Hank Juo*. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS ONE 2012;7(2):e31587. NSC99-2320-B-037-014-MY3, NSC94-2314-B037-104, DOH100-TD-C-111-002. SCI. (Equally corresponding authors).
81. Yang PF, Chen CY, Yu FJ, Yang SF, Chen YT, Kao LC, Wang JY*. A rare complication of Meckel’s diverticulum: a fistula between Meckel’s diverticulum and the appendix. Asian J Surg 2012 Oct;35:163-65. DOH101-TD-C-111-002. SCI.
82. Huang CW, Sun LC, Shih YL, Tsai HL, Chen CW, Yeh YS, Ma CJ, Huang CJ, Wang JY*. The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer. World J Surg Oncol 2012 May 3;10(1):76. DOH101-TD-C-111-002. SCI.
83. Wu TY, Yang IH, Tsai YT, Wang JY, Shiurba R, Hsieh TJ, Chang FR*, Chang WC*. Isodesacetyluvaricin, an annonaceous acetogenin, specifically inhibits gene expression of cyclooxygenase-2. J Nat Prod. 2012 Apr 27;75(4):572-6. SCI.
84. Tsai HL, Chen MJ, Yeh YS, Chen CW, Sun LC, Lu CY, Wang JY*. The comparison of minilaparotomy with conventional laparotomy as the surgical approach in stage I-III colorectal cancer patients: appealing outcomes. Hepato-Gastroenterology 2012 Feb;10;59(119). DOH101-TD-C-111-002. SCI
.85. Chen CF, Huang MY, Huang CJ, Wu CH, Yeh YS, Tsai HL, Ma CJ, Lu CY, Chang SJ, Chen MJ, Wang JY*. An observational study of the efficacy and safety of capecitabine versus bolus infusional 5-Fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer Int J Colorectal Dis 2012 Jun;27(6):727-36.DOH101-TD-C-111-002. SCI.
86. Huang MY, Huang ML, Wang JY*, Lin SR*. Investigation of vascular invasion and genetic polymorphisms of DPD IVS14+1 G>A, UGT1A1 3156 G>A, and UGT1A1 28 tandem repeats in colorectal cancer patients in Taiwan. Genomic Med Bio Mark Health Sci 2012;4:28-29. DOH101-TD-C-111-002.
87. Tung TC, Lin SR, Wang JY, Chung FY. The use of multiple molecular markers as predictors of the clinical prognosis of patients with colorectal cancer. Genomic Med Bio Mark Health Sci 2012;4:30-33.
88. Hung HC, Yen LC, Lin SR, Wang JY. Multiple mRNA markers for the detection of circulating tumor cells in breast cancer patients. Genomic Med Bio Mark Health Sci 2012;4:34-37.
89. Chen CF, Wong WY, Chuang CH, Yeh YS, Tsai KB, Wang JY*. Ruptured ovarian yolk sac tumor combined with hemoperitoneum in a young girl with abdominal blunt injury Genomic Med Biomark Health Sci 2012;4:76-78. DOH101-TD-C-111-002.
90. Ma CJ, Sun LC, Chen FM, Lu CY, Shih YL, Tsai HL, Chuang JF, Wang JY*. A Double-Blind Randomized Study Comparing the Efficacy and Safety of a Composite vs a Conventional Intravenous Fat Emulsion in Postsurgical Gastrointestinal Tumor Patients. Nutr Clin Pract 2012 Jun;27(3):410-5.DOH101-TD-C-111-002. SCI.
91. Huang MY, Wang HM, Tok TS, Chang HJ, Chang MS, Cheng TL, Wang JY*, Lin SR*. EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. DNA Cell Biol 2012 Apr;31(4):625-35. DOH100-TD-C-111-002. SCI.
92. Wang JY, Chen BK, Wang YU, Tsai YT, Chen WC, Chang WC, Hou MF, Wu YC, Chang WC*. Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cellular Signalling2012 Jan;24(1):162-9.NSC 100-2320-B-037-002, 353 NSC 99-2911-I-037-003, KMUH98-8I04, DOH100-TD-C-111-002. SCI.
93. Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY*. Prospective analysis of KRAS wild-type status in patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 regimen as the second/third-line setting. Genet Mol Res 2011 Oct 3;10(4):3002-12. NSC99-2320-B-037-014-MY3. DOH100-TD-C-111-002. SCI.
94. Lu CY, Uen YH, Tsai HL, Chuang SC, Hou MF, Wu DC, Juo SH, Lin SR, Wang JY*. Molecular detection of persistent postoperative circulating tumor cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer 2011 Feb;104:1178–1184. NSC99-2320-B-037-014-MY3, 98CM-KMU-13 & DOH100-TD-C-111-002. SCI.
95. Huang MY, Wang HM, Chang HJ, Hsiao CP, Wang JY*, Lin SR*. Overexpression of S100B, TM4SF4 and OLFM4 Genes are Correlated with Liver Metastasis in Taiwanese Colorectal Cancer Patients. DNA Cell Biol 2012 Jan;31(1):43-9. NSC 99-2320-B-037-014-MY3, DOH100-TD-C-111-002. SCI.
96. Yeh YS, Wang HM, Lin SR, Wang JY*.Prognostic and Molecular Factors in Stage II Colorectal Cancer. Genomic Med Bio Mark Health Sci 2011;3:2-8. (Review article).
97. Huang MY, Wang JY, Chang HJ, Kuo CW, Tok TS, Lin SR. CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer. Oncol Rep 2011 May;25(5):1297-309. SCI.
98. Huang WC, Chai CY, Chen WC, Hou MF, Wang YU, Chiu YC, Lu SR, Chang WC, Juo SH, Wang JY, Chang WC*. Histamine regulates cyclooxygenase 2 gene activation through Orai1-mediated NFκB activation in lung cancer cells. Cell Calcium. 2011 Jul;50(1):27-35. DOH100-TD-C-111-002. NSC 98-2320-B-037-028-MY2. SCI.
99. Hwang CC, Chai HT, Chen HW, Tsai HL, Lu CY, Yu FJ, Huang MY, Wang JY*. S100B Protein Expressions as an Independent Predictor of Early Relapse in UICC Stages II and III Colon Cancer Patients after Curative Resection. Ann Surg Oncol 2011 Jan;18:139-145. SCI. KMUH98-8I04 & DOH99-TD-C-111-002.
100. Huang CC, Ma CJ, Huang WT, Chan TF, Wang JY*. Primary malignant mixed Müllerian tumor arising from the mesorectum with a synchronous ovarian cancer: a case report and review of the literature. J Med Case Reports. 2011 Jan 18;5(1):15. PMID: 21244653. DOH100-TD-C-111-002.
101. Chuang SC, Su YC, Lu CY, Hsu HT, Sun LC, Shih YL, Ker CG, Hsieh JS, Lee KT, Wang JY*. Risk factors for the development of metachronous liver metastasis in colorectal cancer patients after curative resection. World J Surg 2011 Feb;35(2):424-9. SCI. KMUH98-8I04 & DOH99-TD-C-111-002.
102. Huang MY, Huang ML, Chen MJ, Lu CY, Chen CY, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY*. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenetics and Genomics. Pharmacogenet Genomics. 2011 Jan;21(1):18-25. SCI. KMUH98-8I04, ZAFGH 100-05 & DOH99-TD-C-111-002.
103. Lu CY, Shih YL, Sun LC, Chuang JF, Ma CJ, Chen FM, Wu DC, Hsieh JS, Wang JY*. The Inflammatory Modulation Effect of Glutamine-enriched Total Parenteral Nutrition in Postoperative Gastrointestinal Cancer Patients. Am Surg 2011 Jan;77(1):59-64. (corresponding author). SCI.
Shyh-shin Chiou
|
◎學歷◎
|
|
高雄醫學大學 醫學系畢
高雄醫學大學 醫學研究所 博士
|
|
◎現職◎
|
|
高雄醫學大學附設醫院小兒部血液腫瘤科主任
高雄醫學大學附設醫院小兒部血液腫瘤科主治醫師
高雄醫學大學醫學系教授
高雄醫學大學附設檢驗部分子細胞病理及遺傳室主任
高雄醫學大學應用基因體研究中心主任
|
|
◎經歷◎
|
|
高雄醫學大學附設醫院臨床試驗中心主任
高雄醫學大學附設醫院小兒部一般兒科主任
高雄醫學大學研發處行政規劃組組長
高雄醫學大學附設醫院醫學檢驗部血液室主任
高雄醫學大學附設醫院小兒部加護病房主任
高醫醫學大學附設醫院特殊血液病防治中心主任
高雄市立小港醫院小兒科主任
高雄市立小港醫院血庫主任
澳洲雪梨兒童醫院小兒科研究
美國波士頓哈佛大學兒童醫院研究
波士頓Tuft's大學，聖伊麗莎白醫院研究
高雄醫學院小兒科講師
高雄醫學院小兒科總醫師
|
|
◎專長領域◎
|
|
小兒科學、血液學、腫瘤學、分子生物學、造血幹細胞移植
|
Yu-Peng Liu
劉于鵬副教授
Yu-Peng Liu
專長
研究方向
腫瘤的發生與制癌物質誘發、基因突變與基因體多型性具有高度的相關性。近年的研究發現腫瘤起始於一群特定的細胞稱為癌症幹細胞。癌症幹細胞表現出與幹細胞相關的基因並且具有自我更新以及對於化學治療及放射線治療的抗性。在免疫缺陷的老鼠模式中，少量的癌症幹細胞便能夠產生腫瘤。
我們最近的研究發現，常用於治療非小細胞肺癌病患的鉑金屬化療藥物cisplatin，在略低於致死劑量的濃度下，會透過活化Notch訊息傳遞路徑而增加腫瘤中癌症幹細胞(CD133+)的比例。我們實驗室目前利用基因體學分析技術尋找癌症幹細胞的分子標誌，並研究與癌症抗藥性相關的基因與訊息傳遞路徑。此外我們利用基因重組技術建立CD133及其他標記分子之報導基因(reporter gene)模式，應用於高通量藥物篩選，以找出針對癌症幹細胞的新穎治療藥物。
另一方面，我們也對於上皮間質轉換(epithelial-to-mesenchymal transition, EMT)如何影響癌症幹細胞的分化與抗藥性以及對於腫瘤遠端轉移功能的調控相當有興趣。本實驗室除了基礎研究外，也與臨床醫師密切合作，建立轉譯醫學的研究平台，讓實驗室研究方向能切合臨床醫學所面對的問題。
學歷
國立成功大學生命科學研究所博士
經歷
- 高雄醫學大學醫學系基因體醫學科助理教授（現職）
- Department of Human Genetics at Geffen School of Medicine in University of California, Los Angeles (UCLA) 訪問研究員
- Institute of Biodiagnostics, National Research Council of Canada 訪問研究員
- 中央研究院基因體研究中心博士後研究
- 國立成功大學醫學院臨床醫學研究所博士後研究
代表著作
- Liu, Y.P., Hsu, T.I., Liao, W.C., Chen, J.C., Zeng, Y.H., Hsiao, M.*, Lu, P.J.*, 2013. Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer. Cancer Research. Published OnlineFirst August 13, 2013; doi: 10.1158/0008-5472.CAN-13-0518. (IF=8.65, Ranking 11/196, 5.6% in Oncology category) (Accepted).
- Lee, Y.C., Que, J, Chen, Y.C., Lin, J.T., Liou, Y.C., Liao, P.C, Liu, Y.P., Lee, K.H., Lin, L.C., Hsiao, M., Hung, L.Y., Huang, C.Y., Lu, P.J.*, 2013. Pin1 acts as a negative regulator of the G2/M transition through an interplay with the Aurora A/hBora complex. Journal of Cell Science. 2013 Aug 22. [Epub ahead of print], doi:10.1242/jcs.121368. (IF=5.88, Ranking 38/184, 20.7% in Cell Biology) (Accepted).
- Cheng H.C#, Liu Y.P.#, Huang C.Y., Shan Y.S., Lin F.C., Lin L.C., Lee L, Tsai C.H., Hsiao M.*, Lu P.J.*, 2013. Loss of RUNX3 Increases Osteopontin Expression and Promotes Cell Migration in Gastric Cancer. Carcinogenesis. 2013 Jul 8. [Epub ahead of print] DOI: 10.1093/carcin/bgt218. (IF=5.64, Ranking 28/196, 14.3% in Oncology category) (# Equal contribution)
- Liu, Y.P., Chen, H.L., Tzeng, C.C., Lu, P.J, Lee, Y.C., Tseng, C.H., Chen, Y.L, Yang, C.N*. 2013. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation and cell death of breast cancer cells. Breast Cancer Research and Treatment. 2013. 138:383–393 (IF=4.47, Ranking 43/196, 21.9% in Oncology category)
- Liu, Y.P., Yang, C.J., Huang, M.S., Yeh, C.T., Wu, A T.H., Lee, Y.C., Lai, T.C., Lee, C.H., Hsiao, Y.W., Lu, J., Shen, C.N., Lu, P.J.*, Hsiao, M.*, 2013. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Research. 2013. 73(1):406-16. (IF=8.65, Ranking 11/196, 5.6% in Oncology category)
- Tsai H.Y., Yang Y.F., Wu A., Yang C.J., Liu Y.P., Jan Y.H., Lee C.H., Hsiao Y.W., Yeh C.T., Shen C.N., Lu P.J., Huang M.S., Hsiao M.*, 2012. Endoplasmic reticulum ribosome binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene. 2013 Jan 14. doi: 10.1038/onc.2012.514. [Epub ahead of print] (IF=7.36, Ranking 19/196, 9.7% in Oncology category)
- Liu, Y.P. and Hsiao M.*, 2013 Exercise-induced SPARC prevents tumorigenesis of colon cancer. Gut. 2013. 62(6):810-1. Invited Commentary. (IF=10.73, Ranking 3/74, 4.1% in Gastroenterology & Hepatology category)
- Chang, Y.K., Liu, Y.P., Ho, J.H., Hsu, S.C., Lee, O.K.*, 2012. Amine-surface-modified superparamagnetic iron oxide nanoparticles interfere with differentiation of human mesenchymal stem cells. J Orthop Res. 2012. 30(9): 1499-506. (IF=2.88, Ranking 7/63, 11.1% in Orthopedics category)
- Lin, F.C.#, Liu, Y.P.#, Lai, C.H., Shan, Y.S, Cheng, H.C., Hsu, P.I., Lee, C.H., Lee, Y.C., Wanf, H.Y., Wang, C.H., Cheng, J.Q., Hsiao, M.*, Lu, P.J.* 2012. RUNX3-mediated Transcriptional Inhibition of Akt Suppresses Tumorigenesis of Human Gastric Cancer Cells. Oncogene. 2012 Sep 27;31(39):4302-16. (IF=7.36, Ranking 19/196, 9.7% in Oncology category) (# Equal contribution)
- Wu Z, Huang K, Yu J, Le T, Namihira M, Liu Y.P., Zhang J, Xue Z, Cheng L, Fan G*. 2012. Dnmt3a regulates both proliferation and differentiation of mouse neural stem cells. J Neurosci Res. 2012 Oct;90(10):1883-91 (IF=2.97, Ranking 118/251, 47.0% in Neuroscience category).
- Liu, Y.P., Yang, C.S., Chen, M.C., Sun, S.H., Tzeng, S.F.* 2010. Ca2+-dependent reduction of glutamate aspartate transporter Glast expression in astrocytes by persistent P2X7 receptor stimulation. J Neurochem. 2010. 113(1): 213-27. (IF=3.97, Ranking 59/243, 24.3% in Neuroscience category)
- Liu, Y.P., Yang, C.S., Tzeng, S.F.* 2008. Inhibitory regulation of glutamate aspartate transporter GLAST in astrocytes by cadmium-induced calcium influx. J Neurochem. 2008. 105(1):137-50. (IF=3.97, Ranking 59/243, 24.3% in Neuroscience category)
- Yang, C.S., Tzou, B.C., Liu, Y.P., Shyue, S.K., Tzeng, S.F.* 2008. Inhibition of cadmium-induced oxidative injury in rat primary astrocytes by the addition of antioxidants and the reduction of intracellular calcium. J Cell Biochem. 2008. Feb 15; 103(3):825-34. (IF=3.06, Ranking 125/290, 43.1% in Biochemistry & Molecular Biology category)
- Hsiao, H.Y., Mak, O.T., Yang, C.S., Liu, Y.P., Fang, K.M., Tzeng. S.F.* 2007. TNF-a/IFN-g-induced iNOS expression increased by prostaglandin E2 in rat primary astrocytes via EP2-evoked cAMP/PKA and intracellular calcium signaling. Glia. 2007. Jan 15;55(2):214-23. (IF=5.07, Ranking 43/251, 17.1% in Neuroscience category)
- Liu, Y.P., Lin, H.I., Tzeng, S.F.* 2005. Tumor necrosis factor-a and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture. Brain Res. 2005. 1054:152-158. (IF=2.88, Ranking 126/251, 50.2% in Neuroscience category)
- Yeh Y.C., Hwang G.Y., Liu Y.P., Yang V.C., 2002. Identification and expression of scavenger receptor SR-BI in endothelial cells and smooth muscle cells of rat aorta in vitro and in vivo. Atherosclerosis. 2002. 161(1):95-103. (IF=3.71, Ranking 15/67, 22.4% in Peripheral Vascular Disease category)
研討會論文
- Liu Y.P. and Lu P.J.*. 2013 Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. Abstract Number: 272466_1. Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, Hawaii, USA
- Liu, Y.P., Yang C.N. and Lu, P.J.*. 2012 Cisplatin enriches drug resistance CD133 positive cells via activation of Notch Signaling in Non-small Cell Lung Cancer. International Society for Stem Cell Research. Tracking Number: 2012-P-141-ISSCR. Yokohama, Japan.
- Tsai, H.Y., Wu, A.T., Yang, C.J., Lim, C.H., Yang, Y.F., Liu, Y.P., Lee, C.H., Hsiao, Y.W., Jan, Y.H., Yeh, C.T., Shen, C.N., Lu, P.J., Hsiao M*. 2012 Endoplasmic reticulum ribosome binding protein1 (RRBP1) overexpression Is frequently found in lung cancer patients and alleviates intracellular stress induced apoptosis through positive regulation of GRP78 in lung cancer cells. AACR Annual Meeting, Chicago, USA, Mar. 31-Apr.
- Liu, Y.P. and Lu, P.J. 2011. Carboxyl-terminal modulator protein (CTMP) promotes tumorigenesis of breast cancer by enhancing Akt/PKB activation. Global Breast Cancer Conference 2011. Abst. PO03-12. (GBCC2011 Good Poster Presentation Award) Korea
- Liu, Y.P., Lee Y.C., Hsu, C.Y. and Lu, P.J.*. 2011 Carboxyl-terminal modulator protein is a positive regulator of Akt/PKB and plays an oncogenic role in breast cancer. International Symposium on Translational Cancer Research, Taipei, Taiwan, Nov. 20-21, 2011. Abst. 229.
- Tsai, H.Y., Wu, A.T., Yang, C.J., Liu, Y.P., Lee, C.H., Hsiao, Y.W., Jan, Y.H., Yeh, C.T., Shen, C.N., Huang, M.S., Lu, P.J., Hsiao, M*. 2011 RRBP1 overexpression is frequently found in lung cancer patients and alleviates intracellular stress induced apoptosis in lung cancer cell. International Symposium on Translational Cancer Research, Taipei, Taiwan, Nov. 20-21, 2011.
- Liu, Y.P., Lu, P.J., and Hsiao, M. 2011. Cisplatin-induced DNA damage increases the stem-like cancer cells in human non-small cell lung cancer. International Society for Stem Cell Research. Abst. #667. Canada
- Liu, Y.P. and Tzeng, S.F. 2007. Inhibitory regulation of glutamate aspartate transporter GLAST expression in astrocytes by cadmium-induced calcium influx. International Symposium on Cell Signaling and Gene Regulation. Abst. 29. (The best poster presentation Award) Taiwan
- Tzeng, S.F., Liu, Y.P. 2007. Calcium regulation of glutamate aspartate transporter GLAST in astrocytes. Brain'07 and BrainPET'07. Abst. BP48-8W. Japan
- Liu, Y.P., Tzou, B.C., Lin, C.C., Tzeng, S.F. 2005. Regulation of astrocytic cell viability and GLT-1 expression by cadmium. Soc. Neurosci. Abst. 30: 972.10. USA
Chun-Hsiang Tan
譚俊祥 副教授
Chun-Hsiang Tan
專長
神經生理電
神經生物學
研究領域
神經生理學
神經生物學
臨床神經學
學歷
英國劍橋大學博士
高雄醫學大學醫學士
工作經歷
高雄醫學大學臨床醫學研究所助理教授
高雄醫學大學神經部主治醫師
英國倫敦國王學院Wolfson Centre for Age-Related Diseases博士後研究
國立臺灣大學醫學院附設醫院神經部總醫師
國立臺灣大學醫學院附設醫院神經部住院醫師
教授課程
碩士班、博士班專題討論
研究計畫經費補助
| 序號 |
計畫名稱及編號 |
補助單位 |
|
執行期限 |
計劃內
擔任之工作 |
| 1 |
新穎之冷感受機制研究 |
科技部 |
|
2018/8/1 ~ 2021/7/31 |
PI |
| 2 |
探討TRPM2與相關TRP離子通道於溫覺感知與體溫調控之交互作用 |
科技部 |
|
2019/8/1 ~ 2022/7/31 |
PI |
期刊論文發表(近五年)
1. Vilar B, Tan CH, McNaughton PA*. Heat detection by the TRPM2 ion channel. Nature. 2020 Aug;584(7820):E5-E12
2. Su FT, Tai CH, Tan CH, Hwang WJ, Yu RL*. The Development of the Social Functioning Scale for Patients with Parkinson's Disease. Journal of Parkinson's Disease. 2020;10(3):1143-1151
3. Lin CY, Yu RL, Wu RM, Tan CH*. Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease. Scientific Reports. 2019 Dec 12;9(1):18950
4. Fang YJ, Tan CH, Tu SC, Liu CY, Yu RL*. More than an "inverted-U"? An exploratory study of the association between the catechol-o-methyltransferase gene polymorphism and executive functions in Parkinson's disease. PLOS One. 2019 Mar 21;14(3):e0214146
5. Yu RL, Chen PS, Tu SC, Tsao WC, Tan CH*. Emotion-Specific Affective Theory of Mind Impairment in Parkinson’s Disease. Scientific Reports. 2018 Oct 30;8(1):16043
6. Hung CY, Tan CH*. TRP Channels in Nociception and Pathological Pain. Advances in Experimental Medicine and Biology. 2018;1099:13-27
7. Tan CH, McNaughton PA*. TRPM2 and warmth sensation. Pflugers Arch. 2018 May; 470(5):787-798
8. Lu CW, Lo YH, Chen CH, Lin CY, Tsai CH, Chen PJ, Yang YF, Wang CH, Tan CH, Hou MF, Yuan SF*. VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Lett. 2017 Mar 1;388:130-138
9. Tan CH, McNaughton PA*. The TRPM2 ion channel is required for sensitivity to warmth. Nature. 2016 Aug 25;536(7617):460-3
10. Yu RL, Tan CH, Lu YC, Wu RM*. Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson’s disease. Scientific Reports. 2016 Jul 25;6:30424
11. Yu RL, Tan CH, Wu YR, Wu RM, Chiu MJ, Hua MS*. Memory for gist and detail information in patients with Parkinson's disease. BMJ Open. 2015 Nov 20;5(11)
12. Yu RL, Tan CH, Wu RM*. The impact of nocturnal disturbances on daily quality of life in patients with Parkinson’s disease. Neuropsychiatr Dis Treat 2015 Aug 6;11:2005-12
13. Tan CH, McNaughton PA*. TRP channels in heat transduction. TRP Channels in Sensory Transduction (Book chapter)
Hui Ching Wang
專 長
血液性疾病診斷與治療、頭頸癌診斷及治療、消化道惡性腫瘤
現任職稱
高雄醫學大學臨床醫學研究所副教授
高雄醫學大學附設中和紀念醫院血液腫瘤內科主治醫師
學歷
高雄醫學大學醫學士
高雄醫學大學臨床醫學研究所碩士
高雄醫學大學臨床醫學研究所博士
Sin hua Moi
Sin-Hua Moi
Education:
National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan
Ph.D. in Electronic Engineering
Main areas:
Bioinformatics, Machine Learning, Artificial Intelligence, Disease risk model, Medical database
Biography:
Sin-Hua Moi is an assistant professor at the Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. She is a data scientist with specialization in statistics and machine learning algorithms. With over 50 academic papers authored/co-authored, her research interests are focused on bioinformatics, statistical modeling, and disease risk estimation. She is experienced in various data-driven processes such as data exploration, visualization, analysis, data mining, and modeling using R and Python. Her expertise in these programming languages has enabled her to provide valuable insights and solutions to complex data-related problems.
Chia Hsin Liu
|
◎聯絡方式◎
|
|
連絡電話：07-312-1101 ext. 2520
電子信箱：martin@kmu.edu.tw
辦公位置：醫學研究大樓7樓
|
|
|
◎學歷◎
|
|
國立陽明大學(中研院TIGP) 生物醫學資訊研究所 博士
國立清華大學 生物技術研究所 碩士
國立清華大學 生命科學系 學士
|
|
◎研究方向◎
|
|
本實驗室以多體學資料整合分析為主要研究方向，致力於開發創新方法以解析生物醫學資料間的多層次關聯。研究內容涵蓋生物標記探勘、病人藥物反應預測及藥物再利用等精準醫學相關議題。我們與臨床醫師密切合作，結合基礎研究與臨床需求，一方面可在生物標誌或藥物開發初期即明確設定臨床落地目標，另一方面亦能藉由臨床端的回饋，持續深化多體學整合在臨床應用中的可行性與精準度。
目前多體學整合研究多集中於基因體與蛋白質體的層面，但對於代謝體與脂質體等非中心法則的體學資料仍缺乏完善的整合模式。此領域蘊藏豐富的研究潛能與臨床應用價值。本實驗室將結合機器學習、人工智慧與統計模型的技術基礎，並融合在脂質體學研究上的經驗，開發能涵蓋多層級體學資料的整合框架，以探索分子調控網絡的關鍵機制，進而支援疾病診斷與治療策略的設計。
在生物資訊方法的發展上，本實驗室強調分析流程的標準化、套件化與開源化。我們將成熟的方法轉化為可重現的分析工具，發表於國際期刊與開源平台（如CRAN或Bioconductor），促進社群使用與再利用。同時，針對具臨床轉譯潛力的分析模組，我們亦將建立線上資料庫與分析服務平台，整合資料分析、結果可視化與臨床應用介面，提供研究者與臨床醫師更有效的數據支援。
本實驗室的長遠目標是從方法論開發出發，推動多體學整合技術於轉譯醫學與個人化醫療中的實質應用，期望能為未來的精準醫學研究與臨床決策提供堅實的分析基礎與創新方向。
|
|
◎經歷◎
|
|
中國醫藥大學 博士後研究員 (2021-2015)
宏碁股份有限公司 研發主任 (2018-2021)
中央研究院 博士後研究員 (2017-2018)
|
|
◎期刊論文發表◎
|
|
(Selected)
- WJ Lin, CH Liu (co-first), MS Huang, PC Shen, HC Liu, MHTsai, YL Lai, YD Wang, MC Hung, NW Chang, WC Cheng. LipidFun: A Database of Lipid Functions. Bioinformatics, 2025 Mar 13:btaf110. doi: 10.1093/bioinformatics/btaf110.
- Liu CH, Shen PC, Tsai MH, Liu HC, Lin WJ, Lai YL, Wang YD, Hung MC, Cheng WC. LipidSigR: a R-based solution for integrated lipidomics data analysis and visualization. Bioinform Adv. 2025 Mar 10;5(1):vbaf047. doi: 10.1093/bioadv/vbaf047. PMID: 40110562; PMCID: PMC11919814.
- Liu CH, Lai YL, Shen PC, Liu HC, Tsai MH, Wang YD, Lin WJ, Chen FH, Li CY, Wang SC, Hung MC, Cheng WC. DriverDBv4: a multi-omics integration database for cancer driver gene research. Nucleic Acids Res. 2024 Jan 5;52(D1):D1246-D1252. doi: 10.1093/nar/gkad1060. PMID: 37956338; PMCID: PMC10767848.
- Liu CH, Shen PC, Lin WJ, Liu HC, Tsai MH, Huang TY, Chen IC, Lai YL, Wang YD, Hung MC, Cheng WC. LipidSig 2.0: integrating lipid characteristic insights into advanced lipidomics data analysis. Nucleic Acids Res. 2024 May 6:gkae335. doi: 10.1093/nar/gkae335. Epub ahead of print. PMID: 38709887.
- Liu CH, Liu SH, Lai YL, Cho YC, Chen FH, Lin LJ, Peng PH, Li CY, Wang SC, Chen JL, Wu HH, Wu MZ, Sher YP, Cheng WC, Hsu KW. Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma. Comput Struct Biotechnol J. 2022 Aug 22;20:4626-4635. doi: 10.1016/j.csbj.2022.08.042. PMID: 36090818; PMCID: PMC9449502.
- Lai YL, Liu CH (co-first), Wang SC, Huang SP, Cho YC, Bao BY, Su CC, Yeh HC, Lee CH, Teng PC, Chuu CP, Chen DN, Li CY, Cheng WC. Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. Cancers (Basel). 2022 Mar 19;14(6):1565. doi: 10.3390/cancers14061565. PMID: 35326723; PMCID: PMC8946240.
- Su SF, Liu CH (cofirst), Cheng CL, Ho CC, Yang TY, Chen KC, Hsu KH, Tseng JS, Chen HW, Chang GC, Yu SL, Li KC. Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precis Oncol. 2021 Feb 19;5:PO.20.00151. doi: 10.1200/PO.20.00151. PMID: 34036228; PMCID: PMC8140798.
- Chen H-Y, Liu C-H (co-first), Chang Y-H, Yu S-L, Ho B-C, Hsu C-P, et al. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma. Oncotarget; Vol 7, No 8. 2016.
- Liu C-H, Ho B-C, Chen C-L, Chang Y-H, Hsu Y-C, Li Y-C, et al. ePIANNO: ePIgenomics ANNOtation tool. PLoS ONE. 2016;11(2):e0148321. doi: 10.1371/journal.pone.0148321.
- Hsin Liu C, Li K-C, Yuan S. Human protein–protein interaction prediction by a novel sequence-based co-evolution method: co-evolutionary divergence. Bioinformatics. 2013;29(1):92-8. doi: 10.1093/bioinformatics/bts620.
- Liu DY-T, Liu C-H, Lai M-T, Lin H-K, Hseu T-H. Global gene expression profiling of wild type and lysC knockout Escherichia coli W3110. FEMS Microbiology Letters. 2007;276(2):202-6. doi: 10.1111/j.1574-6968.2007.00932.x.
|
